1
|
Heo M, Norton BL, Pericot-Valverde I, Mehta SH, Tsui JI, Taylor LE, Lum PJ, Feinberg J, Kim AY, Arnsten JH, Sprecht-Walsh S, Page K, Murray-Krezan C, Anderson J, Litwin AH. Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study. J Hepatol 2024; 80:702-713. [PMID: 38242324 DOI: 10.1016/j.jhep.2023.12.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Revised: 11/27/2023] [Accepted: 12/20/2023] [Indexed: 01/21/2024]
Abstract
BACKGROUND & AIMS Direct-acting antivirals (DAAs) are highly effective for treating HCV infection even among people who inject drugs (PWID). Yet, little is known about patients' adherence patterns and their association with sustained virologic response (SVR) rates. We aimed to summarize various adherence patterns and determine their associations with SVR. METHODS Electronic blister packs were used to measure daily adherence to once-a-day sofosbuvir/velpatasvir during the 12-week treatment period among active PWIDs. Blister pack data were available for 496 participants who initiated DAAs for whom SVR status was known. Adherence was summarized in multiple patterns, such as total adherent days, consecutive missed days, and early discontinuations. Thresholds for adherence patterns associated with >90% SVR rates were also determined. RESULTS The overall SVR rate was 92.7%, with a median adherence rate of 75%. All adherence patterns indicating greater adherence were significantly associated with achieving SVR. Participant groups with ≥50% (>42/84) adherent days or <26 consecutive missed days achieved an SVR rate of >90%. Greater total adherent days during 9-12 weeks and no early discontinuation were significantly associated with higher SVR rates only in those with <50% adherence. Participants with first month discontinuation and ≥2 weeks of treatment interruption had low SVR rates, 25% and 85%, respectively. However, greater adherent days were significantly associated with SVR (adjusted odds ratio 1.10; 95% CI 1.04-1.16; p <0.001) even among participants with ≥14 consecutive missed days. CONCLUSIONS High SVR rates can be achieved in the PWID population despite suboptimal adherence. Encouraging patients to take as much medication as possible, with <2 weeks consecutive missed days and without early discontinuation, was found to be important for achieving SVR. IMPACT AND IMPLICATIONS People who inject drugs can be cured of HCV in >90% of cases, even with relatively low adherence to direct-acting antivirals, but early discontinuations and long treatment interruptions can significantly reduce the likelihood of achieving cure. Clinicians should encourage people who inject drugs who are living with HCV to adhere daily to direct-acting antivirals as consistently as possible, but if any days are interrupted, to continue and complete treatment. These results from the HERO study are important for patients living with HCV, clinicians, experts writing clinical guidelines, and payers. CLINICAL TRIAL NUMBER NCT02824640.
Collapse
Affiliation(s)
- Moonseong Heo
- Department of Public Health Sciences, Clemson University, Clemson, SC 29605, USA.
| | - Brianna L Norton
- Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, 3330 Kossuth Avenue Bronx, NY 10467, USA
| | - Irene Pericot-Valverde
- Department of Psychology, College of Behavioral, Social, and Health Sciences, Clemson University, Clemson, SC 29634, USA
| | - Shruti H Mehta
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Room E6546, Baltimore, MD 21205, USA
| | - Judith I Tsui
- Department of Medicine, University of Washington, 325 9th Ave., Seattle, WA 98104, USA
| | - Lynn E Taylor
- Department of Pharmacy, University of Rhode Island, Avedesian Hall, 7 Greenhouse Rd, Kingston, RI 02881, USA
| | - Paula J Lum
- Division of HIV, Infectious Disease and Global Medicine, University of California, San Francisco and San Francisco General Hospital, 2540 23rd Street, San Francisco, CA 94110, USA
| | - Judith Feinberg
- Department of Behavioral Medicine and Psychiatry, and Department of Medicine, Section of Infectious Diseases, West Virginia University School of Medicine, 930 Chestnut Ridge Road, Morgantown, WV 26505, USA
| | - Arthur Y Kim
- Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, 55 Fruit St., Boston, MA 02114, USA
| | - Julia H Arnsten
- Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, 3330 Kossuth Avenue Bronx, NY 10467, USA
| | | | - Kimberly Page
- Department of Internal Medicine, University of New Mexico Health Sciences Center, University of New Mexico MSC 10 5550, Albuquerque, NM 87131, USA
| | - Cristina Murray-Krezan
- Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, 200 Meyran Avenue, Suite 300, Pittsburgh, PA 15213, USA
| | - Jessica Anderson
- Department of Internal Medicine, University of New Mexico Health Sciences Center, University of New Mexico MSC 10 5550, Albuquerque, NM 87131, USA
| | - Alain H Litwin
- School of Health Research, Clemson University, Clemson, SC 29605, USA; Department of Medicine, University of South Carolina School of Medicine, 876 W Faris Rd, Greenville, SC 29605, USA; Department of Medicine, Prisma Health, Greenville, SC 29605, USA.
| |
Collapse
|
2
|
Rudolph AE, Nance RM, Bobashev G, Brook D, Akhtar W, Cook R, Cooper HL, Friedmann PD, Frost SDW, Go VF, Jenkins WD, Korthuis PT, Miller WC, Pho MT, Ruderman SA, Seal DW, Stopka TJ, Westergaard RP, Young AM, Zule WA, Tsui JI, Crane HM, Whitney BM, Delaney JAC. Evaluation of respondent-driven sampling in seven studies of people who use drugs from rural populations: findings from the Rural Opioid Initiative. BMC Med Res Methodol 2024; 24:94. [PMID: 38654219 PMCID: PMC11036624 DOI: 10.1186/s12874-024-02206-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Accepted: 03/21/2024] [Indexed: 04/25/2024] Open
Abstract
BACKGROUND Accurate prevalence estimates of drug use and its harms are important to characterize burden and develop interventions to reduce negative health outcomes and disparities. Lack of a sampling frame for marginalized/stigmatized populations, including persons who use drugs (PWUD) in rural settings, makes this challenging. Respondent-driven sampling (RDS) is frequently used to recruit PWUD. However, the validity of RDS-generated population-level prevalence estimates relies on assumptions that should be evaluated. METHODS RDS was used to recruit PWUD across seven Rural Opioid Initiative studies between 2018-2020. To evaluate RDS assumptions, we computed recruitment homophily and design effects, generated convergence and bottleneck plots, and tested for recruitment and degree differences. We compared sample proportions with three RDS-adjusted estimators (two variations of RDS-I and RDS-II) for five variables of interest (past 30-day use of heroin, fentanyl, and methamphetamine; past 6-month homelessness; and being positive for hepatitis C virus (HCV) antibody) using linear regression with robust confidence intervals. We compared regression estimates for the associations between HCV positive antibody status and (a) heroin use, (b) fentanyl use, and (c) age using RDS-1 and RDS-II probability weights and no weights using logistic and modified Poisson regression and random-effects meta-analyses. RESULTS Among 2,842 PWUD, median age was 34 years and 43% were female. Most participants (54%) reported opioids as their drug of choice, however regional differences were present (e.g., methamphetamine range: 4-52%). Many recruitment chains were not long enough to achieve sample equilibrium. Recruitment homophily was present for some variables. Differences with respect to recruitment and degree varied across studies. Prevalence estimates varied only slightly with different RDS weighting approaches, most confidence intervals overlapped. Variations in measures of association varied little based on weighting approach. CONCLUSIONS RDS was a useful recruitment tool for PWUD in rural settings. However, several violations of key RDS assumptions were observed which slightly impacts estimation of proportion although not associations.
Collapse
Affiliation(s)
- Abby E Rudolph
- Department of Epidemiology and Biostatistics, Temple University College of Public Health, 1301 Cecil B Moore Avenue, Ritter Annex 905, Philadelphia, PA, USA
| | - Robin M Nance
- Harborview Medical Center, University of Washington, 325 9th Ave, Box 359931, Seattle, WA, 98106, USA
| | - Georgiy Bobashev
- RTI International, 3040 East Cornwallis Road, P.O. Box 12194, Research Triangle Park, NC, 27709-2194, USA
| | - Daniel Brook
- Division of Epidemiology, College of Public Health, Ohio State University, Columbus, Ohio, 43210, USA
| | - Wajiha Akhtar
- University of Wisconsin-Madison, Population Health Institute, 610 Walnut Street, 575 WARF, Madison, WI, 53726, USA
| | - Ryan Cook
- General Internal Medicine and Geriatrics, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239-3098, USA
| | - Hannah L Cooper
- Rollins School of Public Health, Emory University, Grace Crum Rollins Building, 1518 Clifton Road, Atlanta, Georgia, 30322, USA
| | - Peter D Friedmann
- Baystate Medical Center-University of Massachusetts, Office of Research, UMass Chan Medical School - Baystate, 3601 Main Street, 3rd Floor, Springfield, MA, 01199, USA
| | - Simon D W Frost
- Microsoft Premonition, Microsoft Building 99, 14820 NE 36th St. Redmond, Seattle, WA, 98052, USA
- Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
| | - Vivian F Go
- University of North Carolina-Chapel Hill, 363 Rosenau Hall, CB# 7440, Chapel Hill, NC, 27599, USA
| | - Wiley D Jenkins
- Southern Illinois University, 201 E Madison Street, Springfield, IL, 62702, USA
| | - Philip T Korthuis
- Oregon Health & Science University, 3270 Southwest Pavilion Loop OHSU Physicians Pavilion, Suite 350, Portland, OR, 97239, USA
| | - William C Miller
- The Ohio State University, 302 Cunz Hall, 1841 Neil Ave, Columbus, OH, 43210, USA
| | - Mai T Pho
- University of Chicago, 5841 S. Maryland Avenue, Chicago, IL, 60637, USA
| | - Stephanie A Ruderman
- Harborview Medical Center, University of Washington, 325 9th Ave, Box 359931, Seattle, WA, 98106, USA
| | - David W Seal
- Tulane University, 1440 Canal Street, Suite 2210, New Orleans, LA, 70112, USA
| | - Thomas J Stopka
- Tufts University School of Medicine, Public Health and Community Medicine, 136 Harrison Avenue, Boston, MA, 02111, USA
| | - Ryan P Westergaard
- University of Wisconsin-Madison, 1685 Highland Avenue, 5th Floor, Madison, WI, 53705-2281, USA
| | - April M Young
- University of Kentucky, 760 Press Avenue, Suite 280, Lexington, KY, 40536, USA
| | - William A Zule
- RTI International, 3040 East Cornwallis Road, P.O. Box 12194, Research Triangle Park, NC, 27709-2194, USA
| | - Judith I Tsui
- Harborview Medical Center, University of Washington, 325 9th Ave, Box 359931, Seattle, WA, 98106, USA
| | - Heidi M Crane
- Harborview Medical Center, University of Washington, 325 9th Ave, Box 359931, Seattle, WA, 98106, USA.
| | - Bridget M Whitney
- Harborview Medical Center, University of Washington, 325 9th Ave, Box 359931, Seattle, WA, 98106, USA
| | - Joseph A C Delaney
- Harborview Medical Center, University of Washington and University of Manitoba, University of Washington, 325 9th Ave, Box 359931, Seattle, WA, 98106, USA
| |
Collapse
|
3
|
Robinson-Papp J, Lawrence S, Wadley A, Scott W, George MC, Josh J, O'Brien KK, Price C, Uebelacker L, Edelman EJ, Evangeli M, Goodin BR, Harding R, Nkhoma K, Parker R, Sabin C, Slawek D, Tsui JI, Merlin JS. Priorities for HIV and chronic pain research: results from a survey of individuals with lived experience. AIDS Care 2024:1-11. [PMID: 38588701 DOI: 10.1080/09540121.2024.2334358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2023] [Accepted: 03/19/2024] [Indexed: 04/10/2024]
Abstract
The Global Task Force on Chronic Pain in HIV published seven research priorities in the field of HIV-associated chronic pain in 2019: (1) causes; (2) management; (3) treatment individualization and integration with addiction treatment; (4) mental and social health factors; (5) prevalence; (6) treatment cost effectiveness; and (7) prevention. The current study used a web-based survey to determine whether the research topics were aligned with the priorities of adults with lived experiences of HIV and chronic pain. We also collected information about respondents' own pain and treatment experiences. We received 311 survey responses from mostly US-based respondents. Most respondents reported longstanding, moderate to severe, multisite pain, commonly accompanied by symptoms of anxiety and/or depression. The median number of pain treatments tried was 10 (IQR = 8, 13), with medications and exercise being the most common modalities, and opioids being viewed as the most helpful. Over 80% of respondents considered all research topics either "extremely important" or "very important". Research topic #2, which focused on optimizing management of pain in people with HIV, was accorded the greatest importance by respondents. These findings suggest good alignment between the priorities of researchers and US-based people with lived experience of HIV-associated chronic pain.
Collapse
Affiliation(s)
| | - Steven Lawrence
- Vilcek Institute of Graduate Biomedical Sciences, NYU Grossman School of Medicine, New York, NY, USA
| | - Antonia Wadley
- Brain Function Research Group, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Whitney Scott
- Health Psychology Section, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
- INPUT Pain Unit, Guy's & St Thomas' NHS Foundation Trust
| | | | - Jo Josh
- British HIV Association (BHIVA), London, UK
| | - Kelly K O'Brien
- Department of Physical Therapy, Temerty Faculty of Medicine, University of Toronto
- Rehabilitation Sciences Institute (RSI), University of Toronto
- Institute of Health Policy, Management and Evaluation (IHPME), Dalla Lana School of Public Health University of Toronto, Toronto, Canada
| | - Collen Price
- Canadian HIV/AIDS and Chronic Pain Society, Ottawa, Canada
| | | | | | - Michael Evangeli
- Department of Psychology, Royal Holloway University of London, Egham, UK
| | - Burel R Goodin
- Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, USA
| | - Richard Harding
- Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, Cicely Saunders Institute, King's College London, London, UK
| | - Kennedy Nkhoma
- Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, Cicely Saunders Institute, King's College London, London, UK
| | - Romy Parker
- Department of Anaesthesia and Perioperative Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
| | - Caroline Sabin
- Institute for Global Health, University College London, London, UK
| | - Deepika Slawek
- Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA
| | - Judith I Tsui
- University of Washington School of Medicine, Seattle, WA, USA
| | - Jessica S Merlin
- CHAllenges in Managing and Preventing Pain (CHAMPP) Clinical Research Center, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh
| |
Collapse
|
4
|
Fredericksen RJ, Baker R, Sibley A, Estadt AT, Colston D, Mixson LS, Walters S, Bresett J, Levander XA, Leichtling G, Davy-Mendez T, Powell M, Stopka TJ, Pho M, Feinberg J, Ezell J, Zule W, Seal D, Cooper HLF, Whitney BM, Delaney JAC, Crane HM, Tsui JI. Motivation and context of concurrent stimulant and opioid use among persons who use drugs in the rural United States: a multi-site qualitative inquiry. Harm Reduct J 2024; 21:74. [PMID: 38561753 PMCID: PMC10985853 DOI: 10.1186/s12954-024-00986-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Accepted: 03/12/2024] [Indexed: 04/04/2024] Open
Abstract
BACKGROUND In recent years, stimulant use has increased among persons who use opioids in the rural U.S., leading to high rates of overdose and death. We sought to understand motivations and contexts for stimulant use among persons who use opioids in a large, geographically diverse sample of persons who use drugs (PWUD) in the rural settings. METHODS We conducted semi-structured individual interviews with PWUD at 8 U.S. sites spanning 10 states and 65 counties. Content areas included general substance use, injection drug use, changes in drug use, and harm reduction practices. We used an iterative open-coding process to comprehensively itemize and categorize content shared by participants related to concurrent use. RESULTS We interviewed 349 PWUD (64% male, mean age 36). Of those discussing current use of stimulants in the context of opioid use (n = 137, 39%), the stimulant most used was methamphetamine (78%) followed by cocaine/crack (26%). Motivations for co-use included: 1) change in drug markets and cost considerations; 2) recreational goals, e.g., seeking stronger effects after heightened opioid tolerance; 3) practical goals, such as a desire to balance or alleviate the effects of the other drug, including the use of stimulants to avoid/reverse opioid overdose, and/or control symptoms of opioid withdrawal; and 4) functional goals, such as being simultaneously energized and pain-free in order to remain productive for employment. CONCLUSION In a rural U.S. cohort of PWUD, use of both stimulants and opioids was highly prevalent. Reasons for dual use found in the rural context compared to urban studies included changes in drug availability, functional/productivity goals, and the use of methamphetamine to offset opioid overdose. Education efforts and harm reduction services and treatment, such as access to naloxone, fentanyl test strips, and accessible drug treatment for combined opioid and stimulant use, are urgently needed in the rural U.S. to reduce overdose and other adverse outcomes.
Collapse
Affiliation(s)
| | - R Baker
- Oregon Health & Science University, Portland, USA
| | - A Sibley
- University of North Carolina at Chapel Hill, Chapel Hill, USA
| | - A T Estadt
- The Ohio State University, Colombus, USA
| | - D Colston
- University of North Carolina at Chapel Hill, Chapel Hill, USA
| | | | | | - J Bresett
- Southern Illinois University School of Medicine, Springfield, USA
| | - X A Levander
- Oregon Health & Science University, Portland, USA
| | | | - T Davy-Mendez
- University of North Carolina at Chapel Hill, Chapel Hill, USA
| | - M Powell
- University of Washington, Seattle, USA
| | - T J Stopka
- Tufts University School of Medicine, Department of Public Health and Community Medicine, Medford, USA
| | - M Pho
- University of Chicago, Chicago, USA
| | - J Feinberg
- West Virginia University, Morgantown, USA
| | - J Ezell
- Cornell University, Ithaca, USA
| | - W Zule
- University of North Carolina at Chapel Hill, Chapel Hill, USA
| | - D Seal
- Tulane University, New Orleans, USA
| | | | | | | | - H M Crane
- University of Washington, Seattle, USA
| | - J I Tsui
- University of Washington, Seattle, USA
| |
Collapse
|
5
|
Heidari O, Winiker AK, Pollock S, Sodder S, Tsui JI, Tobin KE. A qualitative exploration of the use of telehealth for opioid treatment: Implications for nurse-managed care. J Clin Nurs 2024. [PMID: 38500003 DOI: 10.1111/jocn.17125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2023] [Revised: 02/25/2024] [Accepted: 03/11/2024] [Indexed: 03/20/2024]
Abstract
AIM To characterise experiences with telehealth for Medications for Opioid Use Disorder (MOUD) services among patients, prescribers, nurses and substance use counsellors to inform future best practices. DESIGN We engaged a qualitative descriptive study design. METHODS Semi-structured interviews were conducted with prescribers (nurse practitioners and physicians, n = 20), nurses and substance use counsellors (n = 7), and patients (n = 20) between June and September 2021. Interviews were verbatim transcribed. Thematic analysis was conducted using a qualitative descriptive method. RESULTS Among both providers and patients, four themes were identified: (1) Difficulties with telehealth connection (2) Flexibility in follow-up and retention, (3) Policy changes that enabled expanded care, (4) Path forward with telehealth. Two additional findings emerged from provider interviews: (1) Expansion of nurse-managed office-based opioid treatment, and (2) Novel methods to engage patients. CONCLUSIONS Patients and providers continued to view telehealth as an acceptable means for delivery and management of MOUD, particularly when utilised in a hybrid manner between in-person visits. Nurse-managed care for this service was evident as nurses extended the breadth of services offered and utilised novel methods such as text messages and management of 'call-in' lines to engage patients. IMPLICATIONS FOR THE PROFESSION AND/OR PATIENT CARE Use of telehealth for MOUD should be incorporated into practice settings to reach patients in a flexible manner. Nurses in particular can use this medium to extend office-based opioid treatment by conducting assessments and expanding capacity for other wrap-around services. IMPACT We identify recommendations for best practices in the use of telehealth for opioid use disorder management and highlight the value of nurse-managed care. REPORTING METHOD The consolidated criteria for reporting qualitative research. PATIENT OR PUBLIC CONTRIBUTION Patients with opioid use disorder and prescribers with experience using telehealth were interviewed for this study.
Collapse
Affiliation(s)
- Omeid Heidari
- School of Nursing, Department of Child, Family, and Population Health Nursing, University of Washington, Seattle, Washington, USA
| | - Abigail K Winiker
- Bloomberg School of Public Health, Department of Health, Behavior, and Society, Johns Hopkins University, Baltimore, Maryland, USA
| | - Sarah Pollock
- Bloomberg School of Public Health, Department of Health, Behavior, and Society, Johns Hopkins University, Baltimore, Maryland, USA
| | - Shereen Sodder
- Bloomberg School of Public Health, Department of Health, Behavior, and Society, Johns Hopkins University, Baltimore, Maryland, USA
| | - Judith I Tsui
- Harborview Medical Center, School of Medicine, Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA
| | - Karin E Tobin
- Bloomberg School of Public Health, Department of Health, Behavior, and Society, Johns Hopkins University, Baltimore, Maryland, USA
| |
Collapse
|
6
|
Tsui JI, Rossi SL, Cheng DM, Bendiks S, Vetrova M, Blokhina E, Winter M, Gnatienko N, Backonja M, Bryant K, Krupitsky E, Samet JH. Pilot RCT comparing low-dose naltrexone, gabapentin and placebo to reduce pain among people with HIV with alcohol problems. PLoS One 2024; 19:e0297948. [PMID: 38408060 PMCID: PMC10896547 DOI: 10.1371/journal.pone.0297948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Accepted: 01/10/2024] [Indexed: 02/28/2024] Open
Abstract
BACKGROUND To estimate the effects on pain of two medications (low-dose naltrexone and gabapentin) compared to placebo among people with HIV (PWH) with heavy alcohol use and chronic pain. METHODS We conducted a pilot, randomized, double-blinded, 3-arm study of PWH with chronic pain and past-year heavy alcohol use in 2021. Participants were recruited in St. Petersburg, Russia, and randomized to receive daily low-dose naltrexone (4.5mg), gabapentin (up to 1800mg), or placebo. The two primary outcomes were change in self-reported pain severity and pain interference measured with the Brief Pain Inventory from baseline to 8 weeks. RESULTS Participants (N = 45, 15 in each arm) had the following baseline characteristics: 64% male; age 41 years (SD±7); mean 2 (SD±4) heavy drinking days in the past month and mean pain severity and interference were 3.2 (SD±1) and 3.0 (SD±2), respectively. Pain severity decreased for all three arms. Mean differences in change in pain severity for gabapentin vs. placebo, and naltrexone vs. placebo were -0.27 (95% confidence interval [CI] -1.76, 1.23; p = 0.73) and 0.88 (95% CI -0.7, 2.46; p = 0.55), respectively. Pain interference decreased for all three arms. Mean differences in change in pain interference for gabapentin vs. placebo, and naltrexone vs. placebo was 0.16 (95% CI -1.38, 1.71; p = 0.83) and 0.40 (95% CI -1.18, 1.99; p = 0.83), respectively. CONCLUSION Neither gabapentin nor low-dose naltrexone appeared to improve pain more than placebo among PWH with chronic pain and past-year heavy alcohol use. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov (NCT4052139).
Collapse
Affiliation(s)
- Judith I. Tsui
- Department of Medicine, Division of General Internal Medicine University of Washington School of Medicine/Harborview Medical Center, Seattle, Washington, United States of America
| | - Sarah L. Rossi
- Department of Medicine, Section of General Internal Medicine, Boston Medical Center, Clinical Addiction Research and Education (CARE) Unit, Boston, Massachusetts, United States of America
| | - Debbie M. Cheng
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, Unites States of America
| | - Sally Bendiks
- Department of Medicine, Section of General Internal Medicine, Boston Medical Center, Clinical Addiction Research and Education (CARE) Unit, Boston, Massachusetts, United States of America
| | | | | | - Michael Winter
- Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, Massachusetts, United States of America
| | - Natalia Gnatienko
- Department of Medicine, Section of General Internal Medicine, Boston Medical Center, Clinical Addiction Research and Education (CARE) Unit, Boston, Massachusetts, United States of America
| | - Miroslav Backonja
- National Center for Complementary and Integrative Health, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Kendall Bryant
- HIV/AIDS Research, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Evgeny Krupitsky
- Pavlov University, St. Petersburg, Russian Federation
- Department of Addictions, V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, St. Petersburg, Russian Federation
| | - Jeffrey H. Samet
- Department of Medicine, Section of General Internal Medicine, Boston University School of Medicine/Boston Medical Center, Clinical Addiction Research and Education (CARE) Unit, Boston, Massachusetts, United States of America
- Department of Community Health Sciences, Boston University School of Public Health, Boston, Massachusetts, United States of America
| |
Collapse
|
7
|
Lopes SS, Pericot-Valverde I, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, Kim AY, Norton BL, Page K, Murray-Krezan C, Anderson J, Karasz A, Arnsten J, Moschella P, Heo M, Litwin AH. Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study. BMC Infect Dis 2024; 24:251. [PMID: 38395747 PMCID: PMC10893697 DOI: 10.1186/s12879-024-09124-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2023] [Accepted: 02/12/2024] [Indexed: 02/25/2024] Open
Abstract
BACKGROUND Self-reported adherence to direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) among persons who inject drugs (PWID) is often an overreport of objectively measured adherence. The association of such overreporting with sustained virologic response (SVR) is understudied. This study among PWID aimed to determine a threshold of overreporting adherence that optimally predicts lower SVR rates, and to explore correlates of the optimal overreporting threshold. METHODS This study analyzed per-protocol data of participants with adherence data (N = 493) from the HERO (Hepatitis C Real Options) study. Self-reported and objective adherence to a 12-week DAA regimen were measured using visual analogue scales and electronic blister packs, respectively. The difference (Δ) between self-reported and objectively measured adherence was calculated. We used the Youden index based on receiver operating characteristic (ROC) curve analysis to identify an optimal threshold of overreporting for predicting lower SVR rates. Factors associated with the optimal threshold of overreporting were identified by comparing baseline characteristics between participants at/above versus those below the threshold. RESULTS The self-reported, objective, and Δ adherence averages were 95.1% (SD = 8.9), 75.9% (SD = 16.3), and 19.2% (SD = 15.2), respectively. The ≥ 25% overreporting threshold was determined to be optimal. The SVR rate was lower for ≥ 25% vs. < 25% overreporting (86.7% vs. 95.8%, p <.001). The factors associated with ≥ 25% Δ adherence were unemployment; higher number of days and times/day of injecting drugs; higher proportion of positive urine drug screening for amphetamine, methamphetamine, and oxycodone, and negative urine screening for THC (tetrahydrocannabinol)/cannabis. CONCLUSIONS Self-reported DAA adherence was significantly greater than objectively measured adherence among PWID by 19.2%. Having ≥ 25% overreported adherence was associated with optimal prediction of lower SVR rates. PWID with risk factors for high overreporting may need to be more intensively managed to promote actual adherence.
Collapse
Affiliation(s)
- Snehal S Lopes
- Department of Public Health Sciences, Clemson University, 29634, Clemson, SC, USA
| | - Irene Pericot-Valverde
- Department of Psychology, College of Behavioral, Social, and Health Sciences, Clemson University, 29634, Clemson, SC, USA
| | - Paula J Lum
- Department of Medicine, University of California, San Francisco, 1001 Potrero Ave, 94110, San Francisco, CA, USA
| | - Lynn E Taylor
- Department of Pharmacy Practice and Clinical Research, University of Rhode Island, 7 Greenhouse Road, 02881, Kingston, RI, USA
| | - Shruti H Mehta
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Room E6546, 21205, Baltimore, MD, USA
| | - Judith I Tsui
- Department of Medicine, University of Washington, 325 9th Ave, 98104, Seattle, WA, USA
| | - Judith Feinberg
- Department of Behavioral Medicine and Psychiatry, West Virginia University School of Medicine, 930 Chestnut Ridge Road, 26505, Morgantown, WV, USA
- Department of Medicine, Section of Infectious Diseases, West Virginia University School of Medicine, 1 Medical Center Drive, 26506, Morgantown, WV, USA
| | - Arthur Y Kim
- Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit St, 02114, Boston, MA, USA
- Harvard Medical School, 02115, Boston, MA, USA
| | - Brianna L Norton
- Albert Einstein College of Medicine, 10461, Bronx, NY, USA
- Department of Medicine, Montefiore Medical Center, 10467, Bronx, NY, USA
| | - Kimberly Page
- Department of Internal Medicine, Health Sciences Center, University of New Mexico, University of New Mexico, MSC 10, 5550, 87131, Albuquerque, NM, USA
| | - Cristina Murray-Krezan
- Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, 15213, Pittsburgh, PA, USA
| | - Jessica Anderson
- Department of Internal Medicine, Health Sciences Center, University of New Mexico, University of New Mexico, MSC 10, 5550, 87131, Albuquerque, NM, USA
| | - Alison Karasz
- UMass Chan Medical School, University of Massachusetts Medical School, 55 Lake Ave, North, 01605, Worcester, MA, USA
| | - Julia Arnsten
- Albert Einstein College of Medicine, 10461, Bronx, NY, USA
- Department of Medicine, Montefiore Medical Center, 10467, Bronx, NY, USA
| | - Phillip Moschella
- Department of Emergency Medicine, Prisma Health, Greenville, SC, USA
- School of Health Research, Clemson University, Clemson, SC, USA
- Department of Medicine, University of South Carolina School of Medicine, 876 W Faris Rd, 29605, Greenville, SC, USA
| | - Moonseong Heo
- Department of Public Health Sciences, Clemson University, 29634, Clemson, SC, USA
| | - Alain H Litwin
- School of Health Research, Clemson University, Clemson, SC, USA.
- Department of Medicine, University of South Carolina School of Medicine, 876 W Faris Rd, 29605, Greenville, SC, USA.
- Department of Medicine, Prisma Health, 29605, Greenville, SC, USA.
| |
Collapse
|
8
|
Leyde S, Price CJ, Colgan DD, Pike KC, Tsui JI, Merrill JO. Mental Health Distress Is Associated With Higher Pain Interference in Patients With Opioid Use Disorder Stabilized on Buprenorphine or Methadone. Subst Use Addctn J 2024:29767342241227402. [PMID: 38327009 DOI: 10.1177/29767342241227402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/09/2024]
Abstract
BACKGROUND The relationships between opioid use disorder (OUD), chronic pain, and mental health distress are complex and multidirectional. The objective of this exploratory study was to examine the relationship between mental health conditions and Chronic pain severity and interference among patients stabilized on either buprenorphine or methadone. METHODS We report baseline data from a randomized trial of a mind-body intervention conducted at 5 outpatient clinics that provided either buprenorphine or methadone treatment. Validated scales were used to measure substance use, mental health distress, and pain severity and interference. Statistical analyses examined the relationship between mental health conditions and pain severity and interference. RESULTS Of 303 participants, 57% (n = 172) reported Chronic pain. A total of 88% (n = 268) were prescribed buprenorphine. Mental health conditions were common, with one-quarter of the sample screening positive for all 3 mental health conditions (anxiety, depression, and posttraumatic stress disorder [PTSD]). Compared to participants without Chronic pain, participants with Chronic pain were more likely to screen positive for moderate-severe anxiety (47% vs 31%); moderate-severe depression (54% vs 41%); and the combination of anxiety, depression, and PTSD (31% vs 18%). Among participants with Chronic pain, mental health conditions were associated with higher pain interference. Pain severity was higher among participants with mental health conditions, but only reached statistical significance for depression. Pain interference scores increased with a higher number of co-occurring mental health conditions. CONCLUSIONS Among individuals stabilized on either buprenorphine or methadone, highly symptomatic and comorbid mental health distress is common and is associated with increased pain interference. Adequate screening for, and treatment of, mental health conditions in patients with OUD and Chronic pain is needed.
Collapse
Affiliation(s)
- Sarah Leyde
- Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA
| | - Cynthia J Price
- Department of Biobehavioral Nursing and Health Informatics, University of Washington, Seattle, WA, USA
| | - Dana D Colgan
- Department of Neurology, Oregon Health & Science University, Portland, OR, USA
- Helfgott Research Institute, National University of Natural Medicine, Portland, OR, USA
| | - Kenneth C Pike
- Department of Child, Family and Population Health Nursing, University of Washington, Seattle, WA, USA
| | - Judith I Tsui
- Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA
| | - Joseph O Merrill
- Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA
| |
Collapse
|
9
|
Soyer EM, Frost MC, Fletcher OV, Ioannou GN, Tsui JI, Edelman EJ, Weiner BJ, Bachrach RL, Chen JA, Williams EC. Perspectives of clinical stakeholders and patients from four VA liver clinics to tailor practice facilitation for implementing evidence-based alcohol-related care. Addict Sci Clin Pract 2024; 19:3. [PMID: 38200496 PMCID: PMC10782537 DOI: 10.1186/s13722-023-00429-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Accepted: 11/29/2023] [Indexed: 01/12/2024] Open
Abstract
BACKGROUND Unhealthy alcohol use (UAU) is particularly dangerous for people with chronic liver disease. Liver clinics may be an important setting in which to provide effective alcohol-related care by integrating evidence-based strategies, such as brief intervention and medications for alcohol use disorder. We conducted qualitative interviews with clinical stakeholders and patients at liver clinics in four Veterans Health Administration (VA) medical centers to understand barriers and facilitators of integrating alcohol-related care and to support tailoring of a practice facilitation implementation intervention. METHODS Data collection and analysis were guided by the Consolidated Framework for Implementation Research (CFIR). Interviews were transcribed and qualitatively analyzed using a Rapid Assessment Process (RAP) guided by the CFIR. RESULTS We interviewed 46 clinical stakeholders and 41 patient participants and analyzed findings based on the CFIR. Clinical stakeholders described barriers and facilitators that ranged from operations/clinic resource-based (e.g., time and capacity, desire for additional provider types, referral processes) to individual perspective and preference-based (e.g., supportiveness of leadership, individual experiences/beliefs). Patient participants shared barriers and facilitators that ranged from relationship-based (e.g., trusting the provider and feeling judged) to resource and education-based (e.g., connection to a range of treatment options, education about impact of alcohol). Many barriers and facilitators to integrating alcohol-related care in liver clinics were similar to those identified in other clinical settings (e.g., time, resources, role clarity, stigmatizing beliefs). However, some barriers (e.g., fellow-led care and lack of integration of liver clinics with addictions specialists) and facilitators (e.g., presence of quality improvement staff in clinics and integrated pharmacists and behavioral health specialists) were more unique to liver clinics. CONCLUSIONS These findings support the possibility of integrating alcohol-related care into liver clinics but highlight the importance of tailoring efforts to account for variation in provider beliefs and experiences and clinic resources. The barriers and facilitators identified in these interviews were used to tailor a practice facilitation implementation intervention in each clinic setting.
Collapse
Affiliation(s)
- Elena M Soyer
- Department of Health Systems and Population Health, University of Washington School of Public Health, 3980 15th Ave NE, Seattle, WA, 98195, USA.
- Health Services Research & Development (HSR&D) Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs (VA) Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA, 98108, USA.
| | - Madeline C Frost
- Department of Health Systems and Population Health, University of Washington School of Public Health, 3980 15th Ave NE, Seattle, WA, 98195, USA
- Health Services Research & Development (HSR&D) Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs (VA) Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA, 98108, USA
| | - Olivia V Fletcher
- Health Services Research & Development (HSR&D) Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs (VA) Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA, 98108, USA
| | - George N Ioannou
- Health Services Research & Development (HSR&D) Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs (VA) Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA, 98108, USA
- Department of Medicine, University of Washington School of Medicine, 325 9th Ave, Seattle, WA, 98104, USA
| | - Judith I Tsui
- Department of Medicine, University of Washington School of Medicine, 325 9th Ave, Seattle, WA, 98104, USA
| | - E Jennifer Edelman
- Yale Schools of Medicine and Public Health, 367 Cedar Street, ES Harkness, Suite 401, New Haven, CT, 06510, USA
| | - Bryan J Weiner
- Department of Health Systems and Population Health, University of Washington School of Public Health, 3980 15th Ave NE, Seattle, WA, 98195, USA
- Department of Global Health, University of Washington School of Public Health, 1959 NE Pacific St, Seattle, WA, 98195, USA
| | - Rachel L Bachrach
- Department of Psychiatry, University of Michigan Medical School, 1301 Catherine St., Ann Arbor, MI, 48109, USA
- Center for Clinical Management Research, VA Ann Arbor Healthcare System, 2215 Fuller Rd, Ann Arbor, MI, 48105, USA
| | - Jessica A Chen
- Health Services Research & Development (HSR&D) Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs (VA) Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA, 98108, USA
- Department of Psychiatry and Behavioral Science, University of Washington School of Medicine, 325 9th Avenue, Seattle, WA, 98104, USA
| | - Emily C Williams
- Department of Health Systems and Population Health, University of Washington School of Public Health, 3980 15th Ave NE, Seattle, WA, 98195, USA
- Health Services Research & Development (HSR&D) Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs (VA) Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA, 98108, USA
| |
Collapse
|
10
|
Foot C, Korthuis PT, Tsui JI, Luo SX, Chan B, Cook RR. Associations between stimulant use and return to illicit opioid use following initiation onto medication for opioid use disorder. Addiction 2024; 119:149-157. [PMID: 37712113 DOI: 10.1111/add.16334] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/06/2022] [Accepted: 07/26/2023] [Indexed: 09/16/2023]
Abstract
AIM The aim of this study was to estimate how ongoing stimulant use affects return to illicit opioid use after initiation onto medication for opioid use disorder (MOUD). DESIGN This was a secondary analysis of pooled data from two clinical trials comparing buprenorphine (BUP-NX) and extended-release naltrexone (XR-NTX). SETTING Thirteen opioid treatment programs and HIV clinics across 10 states in the United States from 2014 to 2019 took part in this study. PARTICIPANTS A total of 528 participants who initiated MOUD as part of trial participation were included. Nearly half (49%) were between 30 and 49 years of age, 69% were male and 66% were non-Hispanic White. MEASUREMENTS The primary outcome was first self-reported day of non-prescribed opioid use following MOUD initiation, and the exposure of interest was daily stimulant use (methamphetamine, amphetamines or cocaine). Both were defined using time-line follow-back. Among participants reporting at least 1 day of illicit opioid use, we also examined relapse to ongoing use, defined as (1) 7 days of continuous opioid use or (2) 4 consecutive weeks with self-reported opioid use, one or more positive urine drug screens (UDS) for opioids or one or more missing UDS. FINDINGS Forty-seven per cent of participants reported stimulant use following MOUD initiation, 58% returned to illicit opioid use and 66% of those relapsed to ongoing use. Stimulant use was strongly associated with increased risk of misusing opioids after MOUD initiation when measured daily [adjusted hazard ratio (aHR) = 9.23, 95% confidence interval (CI) = 6.80-12.50, P < 0.001] and over a 7-day period (aHR = 1.27 for each additional day, CI = 1.18-1.37, P < 0.001). Using stimulants weekly or more often was associated with increased likelihood of relapse to ongoing opioid use compared with less than weekly or no stimulant use (adjusted odds ratio = 2.30, CI = 1.05-5.39, P = 0.044). CONCLUSIONS People initiated on medication for opioid use disorder who subsequently use stimulants appear to be more likely to return to and continue using non-prescribed opioids compared with those without stimulant use. The association appears to be stronger among patients who initiate buprenorphine compared with those who initiate extended-release naltrexone.
Collapse
Affiliation(s)
- Canyon Foot
- Department of Medicine, Section of Addiction Medicine, Oregon Health and Science University, Portland, OR, USA
| | - Philip T Korthuis
- Department of Medicine, Section of Addiction Medicine, Oregon Health and Science University, Portland, OR, USA
| | - Judith I Tsui
- Department of Medicine, University of Washington, Seattle, WA, USA
| | - Sean X Luo
- Division on Substance Use Disorders, Department of Psychiatry, Columbia University, New York, NY, USA
| | - Brian Chan
- Department of Medicine, Section of Addiction Medicine, Oregon Health and Science University, Portland, OR, USA
| | - Ryan R Cook
- Department of Medicine, Section of Addiction Medicine, Oregon Health and Science University, Portland, OR, USA
| |
Collapse
|
11
|
Barry MP, Corcorran MA, Tsui JI, Moreno C, Buskin SE, Guthrie BL, Glick SN. High Seroprevalence of Hepatitis C Virus Among Cisgender Women Who Exchange Sex in the Seattle, Washington Area. Subst Use Addctn J 2024; 45:81-90. [PMID: 38258855 DOI: 10.1177/29767342231208936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/24/2024]
Abstract
BACKGROUND Injection drug use (IDU) is a risk factor for hepatitis C virus (HCV) acquisition and occurs disproportionately among women who exchange sex (WES). However, little is known about HCV epidemiology in this population. We estimated HCV seroprevalence, identified correlates of HCV seropositivity, and characterized social networks by HCV serostatus and IDU history among WES in the Seattle, Washington, area. METHODS This was a secondary analysis of data from the 2016 National HIV Behavioral Surveillance survey in the Seattle, Washington area, a cross-sectional survey that used respondent-driven sampling (RDS) to enroll WES for money or drugs (N = 291). All participants were offered rapid HCV-antibody testing. We estimated HCV seropositivity and used log regression methods to estimate crude and adjusted prevalence ratios (PRs) for correlates of HCV seropositivity among WES. Using RDS recruitment chain data, we computed homophily indices to estimate the extent to which participants were likely to recruit another participant with the same HCV serostatus and IDU history. RESULTS In the study sample of WES in the Seattle, Washington area, 79% reported lifetime IDU and 60% were HCV seropositive. HCV seropositivity was strongly associated with ever injecting drugs (PRadj: 7.7 [3.3, 18.0]). The RDS homophily scores for HCV seropositivity (0.07) and ever injecting drugs (0.02) suggested that participants did not tend to recruit others with the same characteristics beyond what would be expected by chance. CONCLUSION Among this sample of WES in Seattle, Washington area, HCV seroprevalence was high and strongly associated with a history of IDU. The high burden of HCV among WES suggests this marginalized group would benefit from additional harm reduction services and targeted HCV treatment campaigns to reduce forward transmission. We saw little evidence of preferential recruitment among WES who were HCV seropositive or reported a history of IDU, suggesting the potential futility of peer-based referrals for HCV treatment.
Collapse
Affiliation(s)
- Michael P Barry
- Department of Epidemiology, University of Washington, Seattle, WA, USA
- HIV/STD Program, Public Health-Seattle & King County, Seattle, WA, USA
| | - Maria A Corcorran
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA
| | - Judith I Tsui
- Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA, USA
| | - Courtney Moreno
- HIV/STD Program, Public Health-Seattle & King County, Seattle, WA, USA
| | - Susan E Buskin
- Department of Epidemiology, University of Washington, Seattle, WA, USA
- HIV/STD Program, Public Health-Seattle & King County, Seattle, WA, USA
| | - Brandon L Guthrie
- Department of Epidemiology, University of Washington, Seattle, WA, USA
- Department of Global Health, University of Washington, Seattle, WA, USA
| | - Sara N Glick
- Department of Epidemiology, University of Washington, Seattle, WA, USA
- HIV/STD Program, Public Health-Seattle & King County, Seattle, WA, USA
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA
| |
Collapse
|
12
|
Lopes SS, Pericot-Valverde I, Arnsten J, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, Kim AY, Norton BL, Page K, Murray-Krezan C, Anderson J, Moschella P, Heo M, Litwin AH. Self-reported and measured adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs: The HERO study. Int J Drug Policy 2024; 123:104288. [PMID: 38103458 DOI: 10.1016/j.drugpo.2023.104288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Revised: 11/30/2023] [Accepted: 12/02/2023] [Indexed: 12/19/2023]
Abstract
BACKGROUND Objective adherence measures, such as electronic blister pack (BP), for direct-acting antivirals (DAAs) for hepatitis C virus (HCV) treatment have high accuracy, but their use is limited in real practice settings. We examined the association of self-reported adherence using a visual analogue scale (VAS) with objective BP adherence and sustained virologic response (SVR) among people who inject drugs. METHODS We conducted secondary analyses using a subset of participants (N = 493) from the per-protocol sample of the HERO study, a pragmatic randomized trial of HCV treatment interventions that used both VAS and BP to measure adherence to a 12-week sofosbuvir/velpatasvir DAA regimen. Multivariable mixed-effects regression models tested the association of self-report adherence level with longitudinal weekly objective adherence. Multivariable logistic regression tested the association of self-report adherence with SVR. RESULTS The average VAS and BP adherences were 95.1 % (SD = 8.9 %) and 76.0 % (16.0 %), respectively, and the proportion of the participants achieving SVR was 92.9 %. The estimated adjusted mean objective adherence was significantly different (-16 %; 95 % CI: -22 %, -11 %, p < .001) between participants with 100 % and <80 % VAS adherence. The likelihood of SVR was significantly lower for those with <80 % VAS adherence [adjusted OR = 0.07; 95 % CI: 0.02, 0.24; p < .001] compared to those with 100 %. CONCLUSION Self-reported adherence overestimated objective adherence. However, higher self-report adherence was significantly associated with higher objective adherence. Also, self-reported adherence ≥80 % was significantly associated with SVR. Thus, the self-report measure has utility as a monitoring tool for adherence during DAA treatment.
Collapse
Affiliation(s)
- Snehal S Lopes
- Department of Public Health Sciences, Clemson University, Clemson, SC 29634, USA
| | - Irene Pericot-Valverde
- Department of Psychology, College of Behavioral, Social, and Health Sciences, Clemson University, Clemson, SC 29634, USA
| | - Julia Arnsten
- Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Medicine, Montefiore Medical Center, Bronx, NY 10467, USA
| | - Paula J Lum
- Department of Medicine, University of California, 1001 Potrero Ave, San Francisco, CA 94110, USA
| | - Lynn E Taylor
- College of Pharmacy, University of Rhode Island, 7 Greenhouse Road, Kingston, RI 02881, USA
| | - Shruti H Mehta
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615N. Wolfe Street, Room E6546, Baltimore, MD 21205, USA
| | - Judith I Tsui
- Department of Medicine, University of Washington, 325 9th Ave., Seattle, WA 98104, USA
| | - Judith Feinberg
- Department of Behavioral Medicine and Psychiatry, West Virginia University School of Medicine, 930 Chestnut Ridge Road, Morgantown, WV 26505, USA; Department of Medicine, Section of Infectious Diseases, West Virginia University School of Medicine, 930 Chestnut Ridge Road, Morgantown, WV 26505, USA
| | - Arthur Y Kim
- Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA
| | - Brianna L Norton
- Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Medicine, Montefiore Medical Center, Bronx, NY 10467, USA
| | - Kimberly Page
- Department of Internal Medicine, University of New Mexico Health Sciences Center, University of New Mexico MSC 10 5550, Albuquerque, NM 87131, USA
| | - Cristina Murray-Krezan
- Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
| | - Jessica Anderson
- Department of Internal Medicine, University of New Mexico Health Sciences Center, University of New Mexico MSC 10 5550, Albuquerque, NM 87131, USA
| | - Phillip Moschella
- Department of Emergency Medicine, Prisma Health, Greenville, SC, USA; School of Health Research, Clemson University, Clemson, SC, USA; Department of Medicine, University of South Carolina School of Medicine, 876W Faris Rd, Greenville, SC 29605, USA
| | - Moonseong Heo
- Department of Public Health Sciences, Clemson University, Clemson, SC 29634, USA
| | - Alain H Litwin
- School of Health Research, Clemson University, Clemson, SC, USA; Department of Medicine, University of South Carolina School of Medicine, 876W Faris Rd, Greenville, SC 29605, USA; Department of Medicine, Prisma Health, Greenville, SC, USA.
| |
Collapse
|
13
|
Altwies EE, Zinsli KA, Chwastiak L, Tsui JI, Bhatraju EP, Ramchandani MS, Golden MR, Dombrowski JC. Substance Use and Mental Health Comorbidities and Receipt of Specialty Care Among Patients Enrolled in a Low-Barrier HIV Clinic. AIDS Behav 2023; 27:3952-3960. [PMID: 37351687 PMCID: PMC11022825 DOI: 10.1007/s10461-023-04110-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/03/2023] [Indexed: 06/24/2023]
Abstract
Low-barrier care is one model of a differentiated service delivery approach for people with HIV (PWH) who are not engaged in conventionally-organized HIV care. Although psychiatric and substance use disorders are common among patients in low-barrier clinics, approaches to behavioral health service delivery within this context have not been well-described. We conducted a descriptive analysis using retrospective review of medical records to evaluate substance use and psychiatric comorbidities and receipt of behavioral health services among patients in the Max Clinic in Seattle, Washington. Among 227 patients enrolled from 2015 to mid-2020, most had a history of hazardous substance use (85%), a psychiatric diagnosis (69%) or unstable housing (69%) documented in the medical record. Less than half of patients referred for depression treatment (33%) or for opioid use disorder treatment (40%) completed even one specialty care visit. More effective approaches are needed to engage patients in behavioral health services within the context of low-barrier HIV care.
Collapse
Affiliation(s)
- Eden E Altwies
- School of Medicine, University of Washington, Seattle, WA, USA.
| | - Kaitlin A Zinsli
- Department of Epidemiology, University of Washington, Seattle, WA, USA
| | - Lydia Chwastiak
- Department of Psychiatry, University of Washington, Seattle, WA, USA
| | - Judith I Tsui
- Department of Medicine, University of Washington, Seattle, WA, USA
| | | | | | - Matthew R Golden
- Department of Epidemiology, University of Washington, Seattle, WA, USA
- Department of Medicine, University of Washington, Seattle, WA, USA
- Public Health - Seattle & King County HIV/STD Program, Seattle, WA, USA
| | - Julia C Dombrowski
- Department of Epidemiology, University of Washington, Seattle, WA, USA
- Department of Medicine, University of Washington, Seattle, WA, USA
- Public Health - Seattle & King County HIV/STD Program, Seattle, WA, USA
| |
Collapse
|
14
|
Wartko PD, Bobb JF, Boudreau DM, Matthews AG, McCormack J, Lee AK, Qiu H, Yu O, Hyun N, Idu AE, Campbell CI, Saxon AJ, Liu DS, Altschuler A, Samet JH, Labelle CT, Zare-Mehrjerdi M, Stotts AL, Braciszewski JM, Murphy MT, Dryden D, Arnsten JH, Cunningham CO, Horigian VE, Szapocznik J, Glass JE, Caldeiro RM, Phillips RC, Shea M, Bart G, Schwartz RP, McNeely J, Liebschutz JM, Tsui JI, Merrill JO, Lapham GT, Addis M, Bradley KA, Ghiroli MM, Hamilton LK, Hu Y, LaHue JS, Loree AM, Murphy SM, Northrup TF, Shmueli-Blumberg D, Silva AJ, Weinstein ZM, Wong MT, Burganowski RP. Nurse Care Management for Opioid Use Disorder Treatment: The PROUD Cluster Randomized Clinical Trial. JAMA Intern Med 2023; 183:1343-1354. [PMID: 37902748 PMCID: PMC10616772 DOI: 10.1001/jamainternmed.2023.5701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Accepted: 09/01/2023] [Indexed: 10/31/2023]
Abstract
Importance Few primary care (PC) practices treat patients with medications for opioid use disorder (OUD) despite availability of effective treatments. Objective To assess whether implementation of the Massachusetts model of nurse care management for OUD in PC increases OUD treatment with buprenorphine or extended-release injectable naltrexone and secondarily decreases acute care utilization. Design, Setting, and Participants The Primary Care Opioid Use Disorders Treatment (PROUD) trial was a mixed-methods, implementation-effectiveness cluster randomized clinical trial conducted in 6 diverse health systems across 5 US states (New York, Florida, Michigan, Texas, and Washington). Two PC clinics in each system were randomized to intervention or usual care (UC) stratified by system (5 systems were notified on February 28, 2018, and 1 system with delayed data use agreement on August 31, 2018). Data were obtained from electronic health records and insurance claims. An implementation monitoring team collected qualitative data. Primary care patients were included if they were 16 to 90 years old and visited a participating clinic from up to 3 years before a system's randomization date through 2 years after. Intervention The PROUD intervention included 3 components: (1) salary for a full-time OUD nurse care manager; (2) training and technical assistance for nurse care managers; and (3) 3 or more PC clinicians agreeing to prescribe buprenorphine. Main Outcomes and Measures The primary outcome was a clinic-level measure of patient-years of OUD treatment (buprenorphine or extended-release injectable naltrexone) per 10 000 PC patients during the 2 years postrandomization (follow-up). The secondary outcome, among patients with OUD prerandomization, was a patient-level measure of the number of days of acute care utilization during follow-up. Results During the baseline period, a total of 130 623 patients were seen in intervention clinics (mean [SD] age, 48.6 [17.7] years; 59.7% female), and 159 459 patients were seen in UC clinics (mean [SD] age, 47.2 [17.5] years; 63.0% female). Intervention clinics provided 8.2 (95% CI, 5.4-∞) more patient-years of OUD treatment per 10 000 PC patients compared with UC clinics (P = .002). Most of the benefit accrued in 2 health systems and in patients new to clinics (5.8 [95% CI, 1.3-∞] more patient-years) or newly treated for OUD postrandomization (8.3 [95% CI, 4.3-∞] more patient-years). Qualitative data indicated that keys to successful implementation included broad commitment to treat OUD in PC from system leaders and PC teams, full financial coverage for OUD treatment, and straightforward pathways for patients to access nurse care managers. Acute care utilization did not differ between intervention and UC clinics (relative rate, 1.16; 95% CI, 0.47-2.92; P = .70). Conclusions and Relevance The PROUD cluster randomized clinical trial intervention meaningfully increased PC OUD treatment, albeit unevenly across health systems; however, it did not decrease acute care utilization among patients with OUD. Trial Registration ClinicalTrials.gov Identifier: NCT03407638.
Collapse
Affiliation(s)
- Paige D Wartko
- Kaiser Permanente Washington Health Research Institute, Seattle
| | - Jennifer F Bobb
- Kaiser Permanente Washington Health Research Institute, Seattle
- Department of Biostatistics, School of Public Health, University of Washington, Seattle
| | - Denise M Boudreau
- Kaiser Permanente Washington Health Research Institute, Seattle
- Now with Genentech Inc, South San Francisco, California
| | | | | | - Amy K Lee
- Kaiser Permanente Washington Health Research Institute, Seattle
- Now with Kaiser Permanente Washington, Renton
| | - Hongxiang Qiu
- Kaiser Permanente Washington Health Research Institute, Seattle
- Now with Department of Epidemiology and Biostatistics, Michigan State University, East Lansing
| | - Onchee Yu
- Kaiser Permanente Washington Health Research Institute, Seattle
| | - Noorie Hyun
- Kaiser Permanente Washington Health Research Institute, Seattle
| | - Abisola E Idu
- Kaiser Permanente Washington Health Research Institute, Seattle
| | - Cynthia I Campbell
- Division of Research, Kaiser Permanente Northern California, Oakland
- Department of Psychiatry and Behavioral Sciences, University of California, San Francisco
| | - Andrew J Saxon
- Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care System, Seattle, Washington
| | - David S Liu
- National Institute on Drug Abuse Center for Clinical Trials Network, North Bethesda, Maryland
| | - Andrea Altschuler
- Division of Research, Kaiser Permanente Northern California, Oakland
| | - Jeffrey H Samet
- Boston University Schools of Medicine and Public Health, Boston Medical Center, Boston, Massachusetts
| | - Colleen T Labelle
- Boston University Schools of Medicine and Public Health, Boston Medical Center, Boston, Massachusetts
| | - Mohammad Zare-Mehrjerdi
- Department of Family and Community Medicine, UTHealth Houston McGovern Medical School, Houston, Texas
| | - Angela L Stotts
- Department of Family and Community Medicine, UTHealth Houston McGovern Medical School, Houston, Texas
| | - Jordan M Braciszewski
- Center for Health Policy and Health Services Research, Henry Ford Health, Detroit, Michigan
| | | | - Douglas Dryden
- MultiCare Health System, Tacoma, Washington
- Now with Mosaic Medical, Bend, Oregon
| | - Julia H Arnsten
- Montefiore Medical Center, Bronx, New York
- Albert Einstein College of Medicine, Bronx, New York
| | - Chinazo O Cunningham
- Albert Einstein College of Medicine, Bronx, New York
- Now with New York State Office of Addiction Services and Supports, New York
| | - Viviana E Horigian
- Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, Florida
| | - José Szapocznik
- Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, Florida
| | - Joseph E Glass
- Kaiser Permanente Washington Health Research Institute, Seattle
| | - Ryan M Caldeiro
- Mental Health and Wellness Department, Kaiser Permanente Washington, Renton
| | | | - Mary Shea
- Kaiser Permanente Washington Health Research Institute, Seattle
| | - Gavin Bart
- Department of Medicine, Hennepin Healthcare, Minneapolis, Minnesota
- University of Minnesota Medical School, Minneapolis
| | | | - Jennifer McNeely
- Department of Population Health, Grossman School of Medicine, New York University, New York
| | - Jane M Liebschutz
- Center for Research on Health Care, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Judith I Tsui
- Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle
| | - Joseph O Merrill
- Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle
| | - Gwen T Lapham
- Kaiser Permanente Washington Health Research Institute, Seattle
- Department of Health Systems and Population Health, School of Public Health, University of Washington, Seattle
| | - Megan Addis
- Kaiser Permanente Washington Health Research Institute, Seattle
| | - Katharine A Bradley
- Kaiser Permanente Washington Health Research Institute, Seattle
- Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle
- Kaiser Permanente Bernard J Tyson School of Medicine, Pasadena, California
| | - Megan M Ghiroli
- Montefiore Medical Center, Bronx, New York
- Albert Einstein College of Medicine, Bronx, New York
| | - Leah K Hamilton
- Kaiser Permanente Washington Health Research Institute, Seattle
| | - Yong Hu
- Center for Health Policy and Health Services Research, Henry Ford Health, Detroit, Michigan
| | | | - Amy M Loree
- Center for Health Policy and Health Services Research, Henry Ford Health, Detroit, Michigan
| | - Sean M Murphy
- Department of Population Health Sciences, Weill Cornell Medicine, New York, New York
| | - Thomas F Northrup
- Department of Family and Community Medicine, UTHealth Houston McGovern Medical School, Houston, Texas
| | | | | | - Zoe M Weinstein
- Boston University Schools of Medicine and Public Health, Boston Medical Center, Boston, Massachusetts
| | | | | |
Collapse
|
15
|
Batchelder AW, Heo M, Foley JD, Sullivan MC, Lum P, Pericot Valverde I, Taylor LE, Mehta SH, Kim AY, Norton B, Tsui JI, Feinberg J, Page K, Litwin AH. Shame and stigma in association with the HCV cascade to cure among people who inject drugs. Drug Alcohol Depend 2023; 253:111013. [PMID: 37951006 DOI: 10.1016/j.drugalcdep.2023.111013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Revised: 09/26/2023] [Accepted: 10/22/2023] [Indexed: 11/13/2023]
Abstract
BACKGROUND Psycho-social experiences including shame and experienced and internalized stigma have been associated with substance use, HCV infection, and reluctance to disclose HCV status and pursue treatment. These psycho-social barriers have been examined independently for many chronic diseases, including HCV, but to our knowledge have not been quantitatively explored in a large multi-site US-based sample of people who inject drugs (PWID) in HCV treatment. METHODS We examine baseline relationships with HCV-stigma and engagement across the HCV treatment cascade as well as baseline and longitudinal relationships between shame and engagement across the HCV treatment cascade including treatment initiation, adherence, completion, and sustained virologic response (SVR) among a multi-site sample of PWID with HCV, where N=755 were randomized to the pragmatic trial comparing HCV treatment outcomes in modified directly observed treatment (mDOT) or patient navigation, and N=623 initiated treatment. RESULTS While cross-sectional assessments of shame and HCV-stigma were not associated with engagement across the HCV treatment cascade, those whose shame scores decreased compared to those who reported consistently high and increasing levels of shame were significantly more likely to complete HCV treatment (aOR=5.29; 95%CI: 1.56,18.00) and achieve SVR (aOR=6.32; 95%CI: 1.61, 24.87). CONCLUSION Results underscore the relationships between lower levels of shame and health-related behavior and treatment outcomes among PWID and suggest SVR achievement may contribute to reductions in shame or that reductions in shame may contribute to continued treatment and thus SVR.
Collapse
Affiliation(s)
- Abigail W Batchelder
- Behavioral Medicine Program, Psychiatry Department, Massachusetts General Hospital, One Bowdoin Square, Suite 701, Boston, MA 02114, USA; Department of Psychiatry, Harvard Medical School, One Bowdoin Square, Suite 701, Boston, MA 02114, USA; The Fenway Institute, Fenway Health, 1340 Boylston Street, Boston, MA 02215, USA.
| | - Moonseong Heo
- Department of Public Health, College of Behavioral, Social, and Health Sciences, Clemson University, 116 Edwards Hall, Clemson, SC 29634, USA
| | - Jacklyn D Foley
- Behavioral Medicine Program, Psychiatry Department, Massachusetts General Hospital, One Bowdoin Square, Suite 701, Boston, MA 02114, USA; Department of Psychiatry, Harvard Medical School, One Bowdoin Square, Suite 701, Boston, MA 02114, USA
| | - Matthew C Sullivan
- Behavioral Medicine Program, Psychiatry Department, Massachusetts General Hospital, One Bowdoin Square, Suite 701, Boston, MA 02114, USA; Department of Psychiatry, Harvard Medical School, One Bowdoin Square, Suite 701, Boston, MA 02114, USA
| | - Paula Lum
- Department of Medicine, University of California, San Francisco, CA, USA
| | | | - Lynn E Taylor
- College of Pharmacy, University of Rhode Island, Providence, RI, USA
| | - Shruti H Mehta
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | - Arthur Y Kim
- Department of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Brianna Norton
- Department of Medicine, Montefiore Medical Center, Bronx, NY, USA
| | - Judith I Tsui
- Department of Medicine, University of Washington, Seattle, WA, USA
| | - Judith Feinberg
- Department of Behavioral Medicine & Psychiatry and Department of Medicine, West Virginia University School of Medicine, Morgantown, WV, USA
| | - Kim Page
- Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
| | - Alain H Litwin
- Department of Medicine, Clemson University, Clemson, SC, 29634 USA; Department of Medicine, University of South Carolina School of Medicine, Greenville, SC, USA; Department of Medicine, Prisma Health, Greenville, SC, USA.
| |
Collapse
|
16
|
Liu AW, Yang WT, Glick SN, Kim H, Beieler AM, Lan KF, Dhanireddy S, Tsui JI. Stimulant Co-use Is Associated With Patient-directed Discharges in Hospitalized Patients with Opioid Use and Injection Drug Use Related Infections. J Addict Med 2023; 17:746-747. [PMID: 37934554 PMCID: PMC10873529 DOI: 10.1097/adm.0000000000001226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/22/2023]
Affiliation(s)
- Amy W. Liu
- Division of General Internal Medicine, University of Washington, Seattle, WA
| | - Wei-Teng Yang
- Section of Addiction Medicine in Division of General Internal Medicine and Geriatrics, Oregon Health & Science University, Portland, OR
- Department of Medicine, Infectious Diseases Division, Hospital of the University of Pennsylvania, Philadelphia, PA
| | - Sara N. Glick
- Division of Allergy and Infectious Diseases, University of Washington
| | - H.Nina Kim
- Division of Allergy and Infectious Diseases, University of Washington
| | - Alison M. Beieler
- Infectious Disease & Travel Medicine Clinic, Harborview Medical Center, University of Washington
| | - Kristine F. Lan
- Division of Allergy and Infectious Diseases, University of Washington
| | | | - Judith I. Tsui
- Division of General Internal Medicine, University of Washington, Seattle, WA
| |
Collapse
|
17
|
Pericot-Valverde I, Lopes SS, Nahvi S, Thrasher JF, Karasz A, Taylor LE, Mehta SH, Lum PJ, Tsui JI, Page K, Feinberg J, Kim AY, Norton BL, Arnsten JH, Fernandez-Artamendi S, Heo M, Litwin A. Reduction in Depressive Symptoms in People who Inject Drugs who Are Cured of Hepatitis C Virus Infection: The HERO Study. Open Forum Infect Dis 2023; 10:ofad498. [PMID: 38023556 PMCID: PMC10644781 DOI: 10.1093/ofid/ofad498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Accepted: 09/29/2023] [Indexed: 12/01/2023] Open
Abstract
Background Depressive symptoms are prevalent among people who inject drugs (PWID) and people with hepatitis C virus (HCV). We examined changes in depressive symptoms among HCV-infected PWID following direct-acting antiviral treatments to evaluate whether these changes differed by history of depressive symptoms, substance use, or HCV treatment outcome. Methods We conducted a secondary analysis of the HERO Study (NCT02824640), a pragmatic randomized clinical trial among PWID, to test the effectiveness of HCV care models. Depressive symptoms (primary outcome) were measured using the Patient Health Questionnaire (PHQ-9) at baseline, end of treatment (EOT), and at follow-up 12 and 24 weeks after EOT. Sustained virologic response (SVR) was defined as undetectable HCV RNA at ≥12 weeks following EOT. Baseline drug use was defined as having a positive urine screening test for amphetamine, methamphetamine, benzodiazepine, cocaine, cannabis, opiate, or oxycodone. Results The sample (n = 498) was 72.3% male, 64.2% White, and on average 43.9 years old. In patients who achieved SVR (F(3432) = 4.58; P = .004) and those with drug use at baseline (F(3478) = 5.11; P < .01), PHQ-9 scores significantly declined over time, with scores lower at EOT and both follow-ups as compared with baseline. Mean PHQ-9 scores at EOT and follow-ups were significantly lower than at baseline, except for those with no depression or mild depression at baseline. Conclusions This study showed that HCV treatment in PWID is associated with sustained declines in depression up to 24 weeks post-treatment among those who achieve SVR and that drug use does not interfere with improvement in depressive symptoms.
Collapse
Affiliation(s)
| | - Snehal S Lopes
- Department of Public Health Sciences, Clemson University, Clemson, South Carolina, USA
| | - Shadi Nahvi
- Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA
| | - James F Thrasher
- Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA
| | - Alison Karasz
- Department of Family Medicine & Community Health, University of Massachusetts, Worcester, Massachusetts, USA
| | - Lynn E Taylor
- College of Pharmacy, University of Rhode Island. Kingston, Rhode Island, USA
| | - Shruti H Mehta
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
| | - Paula J Lum
- Department of Medicine, University of California, San Francisco, San Francisco, California, USA
| | - Judith I Tsui
- Division of General Internal Medicine, University of Washington, Seattle, Washington, USA
| | - Kimberly Page
- Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA
| | - Judith Feinberg
- Department of Behavioral Medicine & Psychiatry and Department of Medicine, Infectious Diseases, West Virginia University School of Medicine, Morgantown, West Virginia, USA
| | - Arthur Y Kim
- Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Brianna L Norton
- Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA
| | - Julia H Arnsten
- Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA
| | - Sergio Fernandez-Artamendi
- Department of Personality, Assessment, and Psychological Treatment, Universidad de Sevilla, Seville, Spain
| | - Moonseong Heo
- Department of Public Health Sciences, Clemson University, Clemson, South Carolina, USA
| | - Alain Litwin
- Department of Psychology, Clemson University, Clemson, South Carolina, USA
- Department of Medicine, University of South Carolina School of Medicine, Greenville, South Carolina, USA
- Department of Medicine, Prisma Health, Greenville, South Carolina, USA
| |
Collapse
|
18
|
Salow K, Jack HE, Tinsley J, Banta-Green CJ, Kingston S, Iles-Shih M, Tsui JI, Glick S. Racial disparities in use of syringe service programs in King County, WA: a comparison of two cross-sectional surveys. Harm Reduct J 2023; 20:133. [PMID: 37704989 PMCID: PMC10500904 DOI: 10.1186/s12954-023-00868-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2023] [Accepted: 09/05/2023] [Indexed: 09/15/2023] Open
Abstract
BACKGROUND Syringe service programs (SSPs) provide tools to people who inject drugs (PWID) to prevent overdose, reduce the risk of HIV and HCV infection, and reduce injection frequency. While effective, previous research suggests that SSPs may not adequately reach some marginalized or particularly vulnerable subpopulations of PWID. METHODS To identify disparities in SSP use, data from two cross-sectional surveys conducted in King County, Washington were compared: a survey of SSP clients and a community survey of PWID in King County. It was hypothesized that Black PWID, women, and gender minorities would be underrepresented in the SSP survey relative to the general population of PWID. RESULTS SSP clients identified as White at a significantly higher rate than the community sample of PWID (p = 0.030). Black (p < 0.001), American Indian/Alaska Native (p < 0.001), Latinx/Hispanic (p = 0.009), and Native Hawaiian/ Pacific Islander PWID (p = 0.034) were underrepresented in the SSP client survey. The gender of SSP clients was similar to the distribution seen in the community sample of PWID (p = 0.483). CONCLUSIONS Black PWID are underrepresented in Seattle-area SSPs, consistent with studies in other large US cities. Both nationally and in Seattle, overdose deaths have been increasing among Black PWID, and harm reduction strategies are vital to reversing this trend. SSPs should explore and test ways to be more accessible to minority populations.
Collapse
Affiliation(s)
- Katheryn Salow
- School of Medicine, University of Washington, Seattle, USA.
| | - Helen E Jack
- Department of Internal Medicine, University of Washington, Seattle, USA
| | - Joe Tinsley
- HIV/STI/HCV Program, Public Health-Seattle & King County, Seattle, USA
| | - Caleb J Banta-Green
- Department of Psychiatry and Behavioral Sciences, Addictions, Drug and Alcohol Institute, School of Medicine, University of Washington, Seattle, USA
| | - Susan Kingston
- Department of Psychiatry and Behavioral Sciences, Addictions, Drug and Alcohol Institute, School of Medicine, University of Washington, Seattle, USA
| | - Matthew Iles-Shih
- Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, USA
| | - Judith I Tsui
- Department of Internal Medicine, University of Washington, Seattle, USA
| | - Sara Glick
- HIV/STI/HCV Program, Public Health-Seattle & King County, Seattle, USA
- Division of Allergy and Infectious Diseases, School of Medicine, University of Washington, Seattle, USA
| |
Collapse
|
19
|
Tsui JI, Whitney BM, Korthuis PT, Chan B, Pho MT, Jenkins WD, Young AM, Cooper HLF, Friedmann PD, Stopka TJ, de Gijsel D, Miller WC, Go VF, Westergaard R, Brown R, Seal DW, Zule WA, Feinberg J, Smith GS, Mixson LS, Fredericksen R, Crane HM, Delaney JA. Methamphetamine use and utilization of medications for opioid use disorder among rural people who use drugs. Drug Alcohol Depend 2023; 250:110911. [PMID: 37549545 PMCID: PMC10599300 DOI: 10.1016/j.drugalcdep.2023.110911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2023] [Revised: 07/23/2023] [Accepted: 07/24/2023] [Indexed: 08/09/2023]
Abstract
BACKGROUND Methamphetamine use is common among persons with opioid use disorder. This study evaluated associations between methamphetamine use and treatment with agonist medications for opioid use disorder (MOUD, specifically buprenorphine, and/or methadone) in U.S. rural communities. METHODS The Rural Opioid Initiative (ROI) is a consortium spanning 10 states and 65 rural counties that included persons who reported past 30-day use of opioids and/or injection drug use between 1/2018 and 3/2020. Analyses were restricted to participants who had ever used opioids and had data on past 30-day methamphetamine use. Multivariable models examined the relationship between methamphetamine use and utilization of agonist MOUD. RESULTS Among 2899 participants, 2179 (75.2%) also reported recent methamphetamine use. Persons with methamphetamine use compared to those without were younger, more likely to have injected drugs, be unhoused, criminal justice involved, and less likely to have health insurance. Adjusted for age, sex, race, and study site, recent methamphetamine use was associated with lower relative odds of past 30-day methadone treatment (aOR=0.66; 95% CI: 0.45-0.99) and fewer methadone treatment days (aIRR=0.76; 0.57-0.99), but not past 30-day buprenorphine receipt (aOR=0.90; 0.67-1.20), buprenorphine treatment days in past 6 months: aIRR=0.88; 0.69-1.12) or perceived inability to access buprenorphine (aOR=1.12; 0.87-1.44) or methadone (aOR=1.06; 0.76-1.48). CONCLUSION Methamphetamine use is common among persons who use opioids in rural U.S. areas and negatively associated with current treatment and retention on methadone but not buprenorphine. Future studies should examine reasons for this disparity and reduce barriers to methadone for persons who use opioids and methamphetamine.
Collapse
Affiliation(s)
- Judith I Tsui
- Department of Medicine, University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA 98195-6420, USA.
| | - Bridget M Whitney
- Department of Medicine, University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA 98195-6420, USA
| | - P Todd Korthuis
- Department of Medicine, Oregon Health & Science University, 3270 Southwest Pavilion Loop OHSU Physicians Pavilion, Suite 350, Portland, OR 97239, USA
| | - Brian Chan
- Department of Medicine, Oregon Health & Science University, 3270 Southwest Pavilion Loop OHSU Physicians Pavilion, Suite 350, Portland, OR 97239, USA
| | - Mai T Pho
- University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637, USA
| | - Wiley D Jenkins
- Southern Illinois University School of Medicine, Springfield, IL 62794, USA
| | - April M Young
- University of Kentucky, 760 Press Avenue Suite 280, Lexington, KY 40536, USA
| | - Hannah L F Cooper
- Rollins School of Public Health, Emory University, Grace Crum Rollins Building 1518 Clifton Road, Atlanta, GA 30322, USA
| | - Peter D Friedmann
- Office of Research, UMass Chan Medical School - Baystate and Baystate Health, 3601 Main Street, 3rd Floor, Springfield, MA 01199, USA
| | - Thomas J Stopka
- Department of Public Health and Community Medicine, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA
| | - David de Gijsel
- Dartmouth-Hitchcock Medical Center, Section of Infectious Disease and International Health, Lebanon, NH, USA
| | - William C Miller
- The Ohio State University, 346 Cunz Hall 1841 Neil Ave, Columbus, OH 43210, USA
| | - Vivian F Go
- University of North Carolina-Chapel Hill, 363 Rosenau Hall CB# 7440, Chapel Hill, NC 27599, USA
| | - Ryan Westergaard
- University of Wisconsin-Madison, 1685 Highland Avenue, 5th Floor, Madison, WI 53705-2281, USA
| | - Randall Brown
- University of Wisconsin-Madison, 1685 Highland Avenue, 5th Floor, Madison, WI 53705-2281, USA
| | - David W Seal
- Tulane University School of Public Health and Tropical Medicine, 1440 Canal Street, Suite 2210, New Orleans, LA 70112, USA
| | - William A Zule
- RTI International, 3040 E. Cornwallis Road, PO Box 12194, Research Triangle Park, NC 2709-2194, USA
| | - Judith Feinberg
- West Virginia University, 930 Chestnut Ridge Road, PO Box 9156, Morgantown, WV 26505, USA
| | - Gordon S Smith
- West Virginia University, 930 Chestnut Ridge Road, PO Box 9156, Morgantown, WV 26505, USA
| | - L Sarah Mixson
- Department of Medicine, University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA 98195-6420, USA
| | - Rob Fredericksen
- Department of Medicine, University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA 98195-6420, USA
| | - Heidi M Crane
- Department of Medicine, University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA 98195-6420, USA
| | - Joseph A Delaney
- Department of Medicine, University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA 98195-6420, USA
| |
Collapse
|
20
|
Button D, Levander XA, Cook RR, Miller WC, Salisbury-Afshar EM, Tsui JI, Ibragimov U, Jenkins WD, Westergaard RP, Korthuis PT. Substance use disorder treatment and technology access among people who use drugs in rural areas of the United States: A cross-sectional survey. J Rural Health 2023; 39:772-779. [PMID: 36575145 PMCID: PMC10293469 DOI: 10.1111/jrh.12737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
PURPOSE To evaluate how technology access affected substance use disorder (SUD) treatment prior to COVID-19 for people who use drugs in rural areas. METHODS The Rural Opioid Initiative (January 2018-March 2020) was a cross-sectional study of people with prior 30-day injection drug or nonprescribed opioid use from rural areas of 10 states. Using multivariable mixed-effect regression models, we examined associations between participant technology access and SUD treatment. FINDINGS Of 3,026 participants, 71% used heroin and 76% used methamphetamine. Thirty-five percent had no cell phone and 10% had no prior 30-day internet use. Having both a cell phone and the internet was associated with increased days of medication for opioid use disorder (MOUD) use (aIRR 1.29 [95% CI 1.11-1.52]) and a higher likelihood of SUD counseling in the prior 30 days (aOR 1.28 [95% CI 1.05-1.57]). Lack of cell phone was associated with decreased days of MOUD (aIRR 0.77 [95% CI 0.66-0.91]) and a lower likelihood of prior 30-day SUD counseling (aOR 0.77 [95% CI 0.62-0.94]). CONCLUSIONS Expanding US rural SUD treatment engagement via telemedicine may require increased cell phone and mobile network access.
Collapse
Affiliation(s)
- Dana Button
- Division of General Internal Medicine and Geriatrics, Department of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, Oregon, USA
| | - Ximena A. Levander
- Division of General Internal Medicine and Geriatrics, Department of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, Oregon, USA
| | - Ryan R. Cook
- Division of General Internal Medicine and Geriatrics, Department of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, Oregon, USA
| | - William C. Miller
- Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio, USA
| | - Elizabeth M. Salisbury-Afshar
- Department of Family Medicine and Community Health, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA
| | - Judith I. Tsui
- Division of General Internal Medicine, University of Washington, Seattle, Washington, USA
| | - Umedjon Ibragimov
- Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
| | - Wiley D. Jenkins
- Department of Population Science and Policy, Southern Illinois University School of Medicine, Springfield, Illinois, USA
| | - Ryan P. Westergaard
- Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA
| | - P. Todd Korthuis
- Division of General Internal Medicine and Geriatrics, Department of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, Oregon, USA
| |
Collapse
|
21
|
Williams EC, Frost MC, Lodi S, Forman LS, Lira MC, Tsui JI, Lunze K, Kim T, Liebschutz JM, Del Rio C, Samet JH. Influence of patient trust in provider and health literacy on receipt of guideline-concordant chronic opioid therapy in HIV care settings. J Opioid Manag 2023; 19:385-393. [PMID: 37968972 PMCID: PMC11037446 DOI: 10.5055/jom.0812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2023]
Abstract
OBJECTIVE Persons with HIV (PWH) frequently receive opioids for pain. Health literacy and trust in provider may impact patient-provider communication, and thus receipt of guideline-concordant opioid monitoring. We analyzed baseline data of HIV-positive patients on chronic opioid therapy (COT) in a trial to improve guideline-concordant COT in HIV clinics. DESIGN Retrospective cohort study. SETTING Two hospital-based safetynet HIV clinics in Boston and Atlanta. PATIENTS AND PARTICIPANTS A cohort of patients who were ≥18 years, HIV-positive, had received ≥ 3 opioid prescriptions from a study site ≥21 days apart within a 6-month period during the prior year and had ≥1 visit at the HIV clinic in the prior 18 months. MAIN OUTCOME MEASURES Adjusted logistic regression models examined whether health literacy and trust in provider (scale scored 11-55, higher indicates more trust) were associated with: (1) ≥ 2 urine drug tests (UDTs) and (2) presence of an opioid treatment agreement. RESULTS Among 166 PWH, mean trust in provider was 47.4 (SD 6.6); 117 (70 percent) had adequate health literacy. Fifty patients (30 percent) had ≥ 2 UDTs and 20 (12 percent) had a treatment agreement. The adjusted odds ratio (aOR) for a one-point increase in trust in provider was 0.97 for having ≥ 2 UDTs (95 percent CI 0.92-1.02) and 1.03 for opioid treatment agreement (95 percent CI 0.95-1.12). The aOR for adequate health literacy was 0.89 for having ≥ 2 UDTs (95 percent CI 0.42-1.88) and 1.66 for an opioid treatment agreement (95 percent CI 0.52-5.31). CONCLUSIONS Health literacy and trust in provider were not associated with chronic opioid therapy quality outcomes.
Collapse
Affiliation(s)
- Emily C. Williams
- University of Washington, Department of Health Systems and Population Health, Seattle, WA
- Veterans Health Administration (VA) Health Services Research and Development, Center of Innovation for Veteran-Centered and Value-Driven Care, Seattle, WA
| | - Madeline C. Frost
- University of Washington, Department of Health Systems and Population Health, Seattle, WA
- Veterans Health Administration (VA) Health Services Research and Development, Center of Innovation for Veteran-Centered and Value-Driven Care, Seattle, WA
| | - Sara Lodi
- Department of Biostatistics, Boston University School of Public Health, Boston, MA
| | - Leah S. Forman
- Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, MA
| | - Marlene C. Lira
- Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston University School of Medicine, Boston, MA
| | - Judith I. Tsui
- Section of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA
| | - Karsten Lunze
- Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston University School of Medicine, Boston, MA
| | - Theresa Kim
- Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston University School of Medicine, Boston, MA
| | - Jane M. Liebschutz
- Division of General Internal Medicine, Center for Research on Health Care, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Carlos Del Rio
- Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA
- Department of Medicine, Emory University School of Medicine, Atlanta, GA
| | - Jeffrey H. Samet
- Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston University School of Medicine, Boston, MA
- Department of Community Health Sciences, Boston University School of Public Health, Boston, MA
| |
Collapse
|
22
|
Kratina-Hathaway Z, Radick AC, Leroux BG, Blalock K, Kim TW, Darnton J, Saxon AJ, Samet JH, Tsui JI. Methamphetamine use and illicit opioid use during buprenorphine treatment. J Subst Use Addict Treat 2023; 151:208934. [PMID: 37811395 PMCID: PMC10554569 DOI: 10.1016/j.josat.2022.208934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/10/2023]
Abstract
Introduction Although methamphetamine use is rising in the United States, its impacts on patient outcomes among persons undergoing treatment for opioid use disorder (OUD) remain unclear. This study aims to assess the association between baseline methamphetamine/amphetamine (MA/A) use and subsequent illicit opioid use among patients with OUD initiating buprenorphine in an office-based setting. Methods We conducted a secondary analysis of a pilot randomized controlled trial of a behavioral mobile health intervention for buprenorphine adherence conducted over a 12-week study period at two clinic sites. The study defined baseline MA/A use by a positive urine drug test (UDT) and/or self-report of use within the past 30-days. Separate Poisson regression models with robust standard errors evaluated associations between MA/A and: i) illicit opioid use measured by weekly UDT (primary) and ii) self-reported past 30-day use at end of study (secondary). Other secondary outcomes included buprenorphine positive UDTs throughout the study and retention in OUD treatment at both weeks 12 and 24 post-randomization. Results At baseline, 28 (36%) of the 78 participants had MA/A use and use was associated with a statistically significant increase in risk of testing positive for illicit opioids on UDT during the study follow-up period (adjusted relative risk (aRR)=1.54; 95% CI=1.09-2.17; p=0.015), as well as an increased risk for reported past 30-day illicit opioid use at week 12 (aRR=3.86; 95% CI=1.47-10.18; P=0.006). The study found no significant associations between MA/A use and buprenorphine positive UDT or retention in OUD treatment. Conclusions In this sample of patients initiating buprenorphine, methamphetamine/amphetamine use at baseline was associated with illicit opioid use over a 12-week period. These findings demonstrate how co-use of methamphetamine can impede attainment of ideal OUD treatment outcomes.
Collapse
Affiliation(s)
- Zoë Kratina-Hathaway
- University of Washington School of Medicine, 1959 NE Pacific St., Seattle, WA 98195
| | - Andrea C. Radick
- Division of General Internal Medicine, Department of Medicine, University of Washington, Harborview Medical Center, Patricia Steel Building, 401 Broadway, Seattle, WA 98104
| | - Brian G. Leroux
- Department of Biostatistics, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195
| | - Kendra Blalock
- Comagine Health, 10700 Meridian Ave N #100, Seattle, WA 98133
| | - Theresa W. Kim
- Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, 801 Massachusetts Avenue, 1st Floor, Boston, MA 02118
| | - James Darnton
- Division of General Internal Medicine, Department of Medicine, University of Washington, Harborview Medical Center, Patricia Steel Building, 401 Broadway, Seattle, WA 98104
| | - Andrew J. Saxon
- Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care System, 1660 S. Columbian Way (MC: S-116-ATC), Seattle, WA 98108
| | - Jeffrey H. Samet
- Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, 801 Massachusetts Avenue, 1st Floor, Boston, MA 02118
| | - Judith I. Tsui
- Division of General Internal Medicine, Department of Medicine, University of Washington, Harborview Medical Center, Patricia Steel Building, 401 Broadway, Seattle, WA 98104
| |
Collapse
|
23
|
Merlin JS, Hamm M, de Abril Cameron F, Baker V, Brown DA, Cherry CL, Edelman EJ, Evangeli M, Harding R, Josh J, Kemp HI, Lichius C, Madden VJ, Nkhoma K, O'Brien KK, Parker R, Rice A, Robinson-Papp J, Sabin CA, Slawek D, Scott W, Tsui JI, Uebelacker LA, Wadley AL, Goodin BR. The Global Task Force for Chronic Pain in People with HIV (PWH): Developing a research agenda in an emerging field. AIDS Care 2023; 35:1215-1223. [PMID: 33745403 PMCID: PMC10758698 DOI: 10.1080/09540121.2021.1902936] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Accepted: 03/09/2021] [Indexed: 10/21/2022]
Abstract
Chronic pain is a common comorbidity in people with HIV (PWH), with prevalence estimates of 25-85%. Research in this area is growing, but significant gaps remain. A Global Task Force of HIV experts was organized to brainstorm a scientific agenda and identify measurement domains critical to advancing research in this field. Experts were identified through literature searches and snowball sampling. Two online questionnaires were developed by Task Force members. Questionnaire 1 asked participants to identify knowledge gaps in the field of HIV and chronic pain and identify measurement domains in studies of chronic pain in PWH. Responses were ranked in order of importance in Questionnaire 2, which was followed by a group discussion. 29 experts completed Questionnaire 1, 25 completed Questionnaire 2, and 21 participated in the group. Many important clinical and research priorities emerged, including the need to examine etiologies of chronic pain in PWH. Pain-related measurement domains were discussed, with a primary focus on domains that could be assessed in a standardized manner across various cohorts that include PWH in different countries. We collaboratively identified clinical and research priorities, as well as gaps in standardization of measurement domains, that can be used to move the field forward.
Collapse
Affiliation(s)
- Jessica S Merlin
- Division of General Internal Medicine, Section of Palliative Care and Medical Ethics, University of Pittsburgh, Pittsburgh, PA, USA
- Center for Research on Health Care, University of Pittsburgh, Pittsburgh, PA, USA
| | - M Hamm
- Qualitative, Evaluation, and Stakeholder Engagement Research Services, Center for Research on Health Care Data Center, University of Pittsburgh, Pittsburgh, PA, USA
| | - F de Abril Cameron
- Center for Research on Health Care, University of Pittsburgh, Pittsburgh, PA, USA
- Qualitative, Evaluation, and Stakeholder Engagement Research Services, Center for Research on Health Care Data Center, University of Pittsburgh, Pittsburgh, PA, USA
| | - V Baker
- Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, Cicely Saunders Institute, King's College London, London, UK
| | - D A Brown
- Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, Cicely Saunders Institute, King's College London, London, UK
- Therapies Department, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK
| | - C L Cherry
- Alfred Health, Monash University and Burnet Institute, Melbourne, Australia
- University of The Witwatersrand, Johannesburg, South Africa
| | - E J Edelman
- Yale Schools of Medicine and Public Health, New Haven, CT, USA
| | - M Evangeli
- Department of Psychology, Royal Holloway University of London, Egham, UK
| | - R Harding
- Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, Cicely Saunders Institute, King's College London, London, UK
| | - J Josh
- British HIV Association (BHIVA), London, UK
| | - H I Kemp
- Department of Surgery & Cancer, Imperial College London, London, UK
| | - C Lichius
- Center for Research on Health Care, University of Pittsburgh, Pittsburgh, PA, USA
| | - V J Madden
- Pain Management Unit, Department of Anaesthesia and Perioperative Medicine, Neuroscience Institute, University of Cape Town, Cape Town, South Africa
| | - K Nkhoma
- Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, Cicely Saunders Institute, King's College London, London, UK
| | - K K O'Brien
- Department of Physical Therapy, Rehabilitation Sciences Institute (RSI), Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto, Toronto, Canada
| | - R Parker
- Pain Management Unit, Department of Anaesthesia and Perioperative Medicine, Neuroscience Institute, University of Cape Town, Cape Town, South Africa
| | - A Rice
- Department of Surgery & Cancer, Imperial College London, London, UK
| | | | - C A Sabin
- Institute for Global Health, University College London, London, UK
| | - D Slawek
- Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA
| | - W Scott
- Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - J I Tsui
- University of Washington School of Medicine, Seattle, WA, USA
| | - L A Uebelacker
- Brown University School of Medicine, Providence, RI, USA
| | - A L Wadley
- Brain Function Research Group, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - B R Goodin
- Department of Psychology, University of Alabama at Birmingham, Birmingham, AL, USA
| |
Collapse
|
24
|
Idrisov B, Hallgren KA, Michaels A, Soth S, Darnton J, Grekin P, Woolworth S, Saxon AJ, Tsui JI. Workload, Usability, and Engagement with a Mobile App Supporting Video Observation of Methadone Take-Home Dosing: Usability Study. JMIR Hum Factors 2023; 10:e42654. [PMID: 37440298 PMCID: PMC10375394 DOI: 10.2196/42654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Revised: 05/02/2023] [Accepted: 05/25/2023] [Indexed: 07/14/2023] Open
Abstract
BACKGROUND Methadone, a cornerstone of opioid use disorder treatments for many decades, is an essential tool for combatting the opioid epidemic. However, requirements for observing methadone dosing in person through direct observed therapy (DOT) impose significant barriers for many patients. Digital technology can facilitate remote DOT, which could reduce barriers to methadone treatment. Currently, there are limited data on the usability of such technology among patients and counselors in methadone treatment settings. OBJECTIVE The primary objective of this study was to assess the workload, usability, and engagement of a video-based DOT mobile app for patients with opioid use disorder receiving methadone treatment. The secondary objective was to assess the workload, usability, and engagement of the provider-facing app portal used by counselors. METHODS Patients (n=12) and counselors (n=3) who previously tried video DOT for methadone through a smartphone app in an opioid treatment program participated in usability testing sessions. Participants completed essential tasks for video DOT, then provided ratings of workload (NASA Task Load Index), usability (modified System Usability Scale), and engagement (modified Engagement Scale) with the core features of the video DOT program. RESULTS Patients and counselors reported low mental, physical, and temporal demands, successful performance, low effort, and low frustration associated with activities. Patients reported high usability (mean 85, SD 9.5) and engagement (mean 3.8, SD 1.1); counselors reported moderate usability (mean 43.3, SD 17.7) and engagement (mean 2.81, SD 0.63). CONCLUSIONS A mobile health app that facilitates video-based DOT for methadone required a low workload for patients and counselors and was highly usable for patients in an opioid treatment program; however, there are opportunities to improve usability and engagement for the counselor-facing portal.
Collapse
Affiliation(s)
- Bulat Idrisov
- Department of Health Systems and Population Health, University of Washington, Seattle, WA, United States
| | - Kevin A Hallgren
- Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, United States
| | - Alyssa Michaels
- Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, United States
| | - Sean Soth
- Evergreen Treatment Services, Seattle, WA, United States
| | - James Darnton
- Evergreen Treatment Services, Seattle, WA, United States
- Division of General Internal Medicine, University of Washington, Seattle, WA, United States
| | - Paul Grekin
- Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, United States
- Evergreen Treatment Services, Seattle, WA, United States
| | | | - Andrew J Saxon
- Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, United States
- Center of Excellence in Substance Addiction Treatment and Education, Veterans Affairs Puget Sound Health Care System, Seattle, WA, United States
| | - Judith I Tsui
- Division of General Internal Medicine, University of Washington, Seattle, WA, United States
| |
Collapse
|
25
|
Bhatraju EP, Radick AC, Leroux BG, Kim TW, Samet JH, Tsui JI. Buprenorphine adherence and illicit opioid use among patients in treatment for opioid use disorder. Am J Drug Alcohol Abuse 2023; 49:511-518. [PMID: 37369019 DOI: 10.1080/00952990.2023.2220876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/14/2022] [Revised: 05/23/2023] [Accepted: 05/28/2023] [Indexed: 06/29/2023]
Abstract
Background: Buprenorphine is a partial mu opioid agonist medication that has been shown to decrease non-prescribed opioid use, cravings, and opioid related morbidity and mortality. There is an assumption that full adherence is needed to achieve ideal treatment outcomes, and that non-adherence is associated with ongoing opioid use. However, literature documenting the strength of that assertion is lacking.Objectives: Evaluate the association between daily buprenorphine adherence and illicit opioid use.Methods: Secondary analysis of a 12-week randomized controlled trial of adults with opioid use disorder who recently initiated buprenorphine. Weekly study visits included self-report of daily buprenorphine adherence over the past 7 days (Timeline Follow Back method) and urine drug tests (UDT). A log-linear regression model accounting for clustering by participant was used to assess the association between buprenorphine adherence and illicit opioid use. Buprenorphine adherence was measured as a continuous variable (0-7 days).Results: Among 78 participants (56 men, 20 women, 2 nonbinary) with 737 visits, full 7-day adherence was reported at 70% of visits. The predominant form of non-adherence was missed doses (92% of cases). Each additional day of adherence was associated with an 8% higher rate of negative UDT for illicit opioids (RR = 1.08; 95% CI:1.03-1.13, p = .0002).Conclusion: In this sample of participants starting buprenorphine, missed doses were not uncommon. Fewer missed days was significantly associated with a lower risk of illicit opioid use. These findings suggest that efforts to minimize the number of missed days of buprenorphine are beneficial for treatment outcomes.
Collapse
Affiliation(s)
- Elenore P Bhatraju
- Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA, USA
| | - Andrea C Radick
- Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA, USA
| | - Brian G Leroux
- Department of Biostatistics, University of Washington, Seattle, WA, USA
| | - Theresa W Kim
- Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center Boston, Boston, MA, USA
| | - Jeffrey H Samet
- Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center Boston, Boston, MA, USA
| | - Judith I Tsui
- Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA, USA
| |
Collapse
|
26
|
Tsui JI, Stephens D, Collins B, Denisiuk E, Hallgren KA, Blalock KL, Klein JW, Jack HE, Merrill JO. Co-use of Methamphetamine Is Associated With Lower Rates of Linkage to Outpatient Treatment for Hospitalized Patients Who Initiate Buprenorphine. J Addict Med 2023; 17:491-492. [PMID: 37579119 PMCID: PMC10350466 DOI: 10.1097/adm.0000000000001129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- Judith I. Tsui
- Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA
| | | | - Brett Collins
- Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, WA
| | - Eric Denisiuk
- Department of Anesthesiology, The Ohio State University, Columbus, OH
| | - Kevin A. Hallgren
- Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA
| | - Kendra L. Blalock
- Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA
| | - Jared W. Klein
- Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA
| | - Helen E. Jack
- Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA
| | - Joseph O. Merrill
- Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA
| |
Collapse
|
27
|
Geist ML, Radick AC, Tsui JI, Blalock KL, Adwell A, Tamru E, Connolly NC, James JR. Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study. Addict Sci Clin Pract 2023; 18:33. [PMID: 37231486 PMCID: PMC10210339 DOI: 10.1186/s13722-023-00389-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2022] [Accepted: 05/05/2023] [Indexed: 05/27/2023] Open
Abstract
BACKGROUND This study examined associations between receipt of hepatitis C (HCV) treatment and retention in office-based opioid treatment (OBOT) care. METHODS We conducted a retrospective cohort study of HCV-infected patients who initiated OBOT treatment between December 2015 and March 2021 to characterize HCV treatment and assess associations with OBOT retention. HCV treatment was characterized as no treatment, early treatment (< 100 days since OBOT initiation) or late treatment (≥ 100 days). We evaluated associations between HCV treatment and cumulative days in OBOT. A secondary analysis using Cox Proportional Hazards regression was done to determine the rate of discharge over time when comparing those who did versus did not receive HCV treatment as a time-varying covariate. We also analyzed a subset of patients retained at least 100 days in OBOT care and evaluated whether HCV treatment during that period was associated with OBOT retention beyond 100 days. RESULTS Of 191 HCV-infected OBOT patients, 30% initiated HCV treatment, of whom 31% received early treatment and 69% received late treatment. Median cumulative duration in OBOT was greater among those who received HCV treatment (any: 398 days, early: 284 days and late: 430 days) when compared to those who did not receive treatment (90 days). Compared to no HCV treatment, there were 83% (95% CI: 33-152%, P < 0.001), 95% (95% CI: 28%-197%, p = 0.002 and 77% (95% CI: 25-153%, p = 0.002) more cumulative days in OBOT for any, early and late HCV treatment, respectively. HCV treatment was associated with a lower relative hazard for discharge/drop-out, although results did not meet statistical significance (aHR = 0.59;95% CI: 0.34-1.00; p = 0.052). Among the subset of 84 patients retained in OBOT at least 100 days, 18 received HCV treatment during that period. Compared to those who did not receive treatment within the first 100 days, those who received treatment had 57% (95% CI: -3%-152%, p = 0.065) more subsequent days in OBOT. CONCLUSIONS A minority of HCV-infected patients received HCV treatment after initiating OBOT treatment, but those who did had better retention. Further efforts are needed to facilitate rapid HCV treatment and evaluate whether early HCV treatment improves OBOT engagement.
Collapse
Affiliation(s)
- Mary L Geist
- University of Washington School of Medicine, 1959 NE Pacific St, Seattle, WA, 98195, USA
| | - Andrea C Radick
- Division of General Internal Medicine, Department of Medicine, Harborview Medical Center, University of Washington School of Medicine, 325 Ninth Avenue, P. O. Box 359780, Seattle, WA, 98104, USA
| | - Judith I Tsui
- Division of General Internal Medicine, Department of Medicine, Harborview Medical Center, University of Washington School of Medicine, 325 Ninth Avenue, P. O. Box 359780, Seattle, WA, 98104, USA
| | - Kendra L Blalock
- Division of General Internal Medicine, Department of Medicine, Harborview Medical Center, University of Washington School of Medicine, 325 Ninth Avenue, P. O. Box 359780, Seattle, WA, 98104, USA
| | - Addy Adwell
- Harborview Medical Center, 325 Ninth Avenue, P.O. Box 359780, Seattle, WA, 98104, USA
| | - Elsabeth Tamru
- Harborview Medical Center, 325 Ninth Avenue, P.O. Box 359780, Seattle, WA, 98104, USA
| | - Nancy C Connolly
- Division of General Internal Medicine, Department of Medicine, Harborview Medical Center, University of Washington School of Medicine, 325 Ninth Avenue, P. O. Box 359780, Seattle, WA, 98104, USA
| | - Jocelyn R James
- Division of General Internal Medicine, Department of Medicine, Harborview Medical Center, University of Washington School of Medicine, 325 Ninth Avenue, P. O. Box 359780, Seattle, WA, 98104, USA.
| |
Collapse
|
28
|
Sue KL, Chawarski M, Curry L, McNeil R, Coupet E, Schwartz RP, Wilder C, Tsui JI, Hawk KF, D’Onofrio G, O’Connor PG, Fiellin DA, Edelman EJ. Perspectives of Clinicians and Staff at Community-Based Opioid Use Disorder Treatment Settings on Linkages With Emergency Department-Initiated Buprenorphine Programs. JAMA Netw Open 2023; 6:e2312718. [PMID: 37163263 PMCID: PMC10173026 DOI: 10.1001/jamanetworkopen.2023.12718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Accepted: 03/24/2023] [Indexed: 05/11/2023] Open
Abstract
Importance An increasing number of emergency departments (EDs) are initiating buprenorphine for opioid use disorder (OUD) and linking patients to ongoing community-based treatment, yet community-based clinician and staff perspectives regarding this practice have not been characterized. Objective To explore perspectives and experiences regarding ED-initiated buprenorphine among community-based clinicians and staff in geographically distinct regions. Design, Setting, and Participants This qualitative study reports findings from Project ED Health, a hybrid type 3 effectiveness-implementation study designed to evaluate the impact of implementation facilitation on ED-initiated buprenorphine with referral to ongoing medication treatment. Clinicians and staff from community-based treatment programs were identified by urban academic EDs as potential referral sites for ongoing OUD treatment in 4 cities across the US in a formative evaluation as having the capability to continue medication treatment. Focus groups were held from April 1, 2018, to January 11, 2019, to examine community OUD treatment clinician and staff perspectives on accepting patients who have received ED-initiated buprenorphine. Data were analyzed from August 2020 to August 2022. Main Outcomes and Measures Data collection and analysis were grounded in the Promoting Action on Research Implementation in Health Services (PARIHS) implementation science framework, focusing on domains including evidence, context, and facilitation. Results A total of 103 individuals (mean [SD] age, 45.3 [12.0] years; 76 female and 64 White) participated in 14 focus groups (groups ranged from 3-22 participants). Participants shared negative attitudes toward buprenorphine and variable attitudes toward ED-initiated buprenorphine. Prominent barriers included the community site treatment capacity and structure as well as payment and regulatory barriers. Perceived factors that could facilitate this model included additional substance use disorder training for ED staff, referrals and communication, greater inclusion of peer navigators, and addressing sociostructural marginalization that patients faced. Conclusions and Relevance In this study of community-based clinicians and staff positioned to deliver OUD treatment, participants reported many barriers to successful linkages for patients who received ED-initiated buprenorphine. Strategies to improve these linkages included educating communities and programs, modeling low-barrier philosophies, and using additional staff trained in addiction as resources to improve transitions from EDs to community partners.
Collapse
Affiliation(s)
- Kimberly L. Sue
- Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
- Yale Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut
| | - Marek Chawarski
- Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut
- Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut
| | - Leslie Curry
- Health Policy and Management, Yale School of Public Health, New Haven, Connecticut
| | - Ryan McNeil
- Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
- Yale Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut
| | - Edouard Coupet
- Yale Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut
- Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut
| | | | - Christine Wilder
- Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio
| | - Judith I. Tsui
- Department of Medicine, University of Washington School of Medicine, Seattle
| | - Kathryn F. Hawk
- Yale Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut
- Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut
| | - Gail D’Onofrio
- Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
- Yale Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut
- Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut
| | - Patrick G. O’Connor
- Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
- Yale Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut
| | - David A. Fiellin
- Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
- Yale Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut
- Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut
- Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, Connecticut
| | - E. Jennifer Edelman
- Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
- Yale Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut
- Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, Connecticut
| |
Collapse
|
29
|
Radick AC, James J, Leroux BG, Kim TW, Saxon AJ, Samet JH, Tsui JI. Use of Video Directly Observed Therapy and Characteristics Associated With Use Among Patients Treated With Buprenorphine in an Office-based Setting. J Addict Med 2023; 17:300-304. [PMID: 37267172 PMCID: PMC10123169 DOI: 10.1097/adm.0000000000001103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
OBJECTIVES Video directly observed therapy (video DOT) is a tool for confirming buprenorphine adherence that could complement the use of urine toxicology; research is needed to characterize the patients who are receptive and able to use this technology. We aimed to describe video DOT utilization and assess participant characteristics associated with use. METHODS We performed a secondary analysis of data from a pilot randomized controlled trial of adults who recently initiated sublingual buprenorphine in office-based programs, restricting to intervention arm participants, which consisted of 12 weeks of video DOT via a mobile health technology platform. Participants were instructed to record at least 1 daily video of buprenorphine self-administration. Poisson regression models with robust standard errors were used to measure associations between participant characteristics and frequency of submitted videos. RESULTS The sample included 39 participants. Of 3276 possible videos, 1002 (31%) were submitted. Age ≥40 years (relative risk [RR], 2.54 [95% confidence interval {CI}, 1.31-4.91]) and once-daily buprenorphine dosing (RR, 3.10 [95% CI, 1.76-5.48]) were positively associated with video submissions. Non-White race (RR, 0.43 [95% CI, 0.19-0.97]), less than high school education (RR, 0.27 [95% CI, 0.10-0.74]), history of previous buprenorphine treatment (RR, 0.50 [95% CI, 0.25-0.97]), and ≥3 previous treatment attempts (RR, 0.16 [95% CI, 0.07-0.37]) were negatively associated. CONCLUSIONS Video DOT utilization resulted in about a third of expected videos, although there were differences in use according to age, race, buprenorphine treatment factors, and educational status. Such differences underscore that mobile-health interventions such as video DOT may not be equally used by all patients.Trial Registration : ClinicalTrails.gov , NCT03779997 , registered on December 19, 2018.
Collapse
Affiliation(s)
- Andrea C Radick
- From the Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA (ACR, JJ, JIT); Department of Biostatistics, University of Washington, Seattle WA (BGL); Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA (TWK, JHS); and Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA (AJS)
| | | | | | | | | | | | | |
Collapse
|
30
|
Tsui JI, Lum PJ, Taylor LE, Mehta SH, Feinberg J, Kim AY, Norton BL, Niu J, Heo M, Arnsten J, Pericot-Valverde I, Thomas A, Blalock KL, Radick A, Murray-Krezan C, Page K, Litwin AH. Injecting practices during and after hepatitis C treatment and associations with not achieving cure among persons who inject drugs. Drug Alcohol Depend 2023; 247:109878. [PMID: 37150144 DOI: 10.1016/j.drugalcdep.2023.109878] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/13/2023] [Revised: 04/07/2023] [Accepted: 04/13/2023] [Indexed: 05/09/2023]
Abstract
BACKGROUND Persons who inject drugs (PWID) are a key population for hepatitis C virus (HCV) treatment. Study aims were to describe injection practices of PWID during HCV treatment with direct-acting antivirals (DAAs) and assess whether injection practices were associated with not achieving a sustained virologic response (SVR). METHODS Secondary analysis of the HERO Study (ClinicalTrials.gov, NCT02824640), a pragmatic randomized trial in 8 U.S. states to evaluate the effectiveness of HCV care models among active PWID seen in opioid treatment programs and community clinics. Frequency, sharing and reuse of injecting equipment were assessed at baseline, end-of-treatment (EOT) and quarterly visits up to 60 weeks post-treatment. Generalized Estimating Equations logistic regression models with linear spline were used to compare trends in injecting behaviors during vs. post-treatment. Multivariable logistic regression models explored associations between injecting behaviors during treatment and lack of SVR. RESULTS Among 501 participants, 27% were female, 35% were non-white, mean age was 44 (SD 11.5) years and nearly half (49%) were unhoused. At baseline, 41% reported receptive sharing of injecting equipment, declining to 16% at EOT visit. Receptive sharing of cookers, rinses, or needles/syringes during treatment was associated with a nearly 5-fold increase in not achieving SVR (adjusted odds ratio (aOR)=4.83; 95% CI: 2.26, 10.28) as was reuse of one's own needles/syringes (aOR=2.37; 95% CI: 1.11, 4.92). CONCLUSIONS PWID in the HERO study adopted safer injecting behaviors during DAA treatment; receptive sharing of injecting equipment and reuse of one's own equipment during treatment were associated with not achieving cure.
Collapse
Affiliation(s)
- Judith I Tsui
- Division of General Internal Medicine, University of Washington, 325 9th Ave, Seattle, WA98104, USA.
| | - Paula J Lum
- Department of Medicine, University of California, San Francisco, 1001 Potrero Ave, San Francisco, CA94110, USA
| | - Lynn E Taylor
- College of Pharmacy, University of Rhode Island, 80 Washington Street, Providence, RI02903, USA; HIV and Viral Hepatitis Services, CODAC Behavioral Health, Providence, RI02909, USA
| | - Shruti H Mehta
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615N. Wolfe Street, Room E6546, Baltimore, MD21205, USA
| | - Judith Feinberg
- Department of Behavioral Medicine & Psychiatry and Department of Medicine, Infectious Diseases, West Virginia University School of Medicine, 930 Chestnut Ridge Road, Morgantown, WV26505, USA
| | - Arthur Y Kim
- Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, 55 Fruit St, Boston, MA02114, USA
| | - Brianna L Norton
- Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, 3330 Kossuth Avenue Bronx, NY10467, USA
| | - Jiajing Niu
- Department of Public Health Sciences, Clemson University, 605 Grove Road, Clemson, SC29605, USA
| | - Moonseong Heo
- Department of Public Health Sciences, Clemson University, 605 Grove Road, Clemson, SC29605, USA
| | - Julia Arnsten
- Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, 3330 Kossuth Avenue Bronx, NY10467, USA
| | - Irene Pericot-Valverde
- Department of Psychology, Clemson University, 418 Bracket Hall, Clemson, SC29634, USA; Clemson University School of Health Research605 Grove RoadGreenvilleSC29605, USA
| | - Aurielle Thomas
- College of Pharmacy, University of Rhode Island, 80 Washington Street, Providence, RI02903, USA
| | - Kendra L Blalock
- Division of General Internal Medicine, University of Washington, 325 9th Ave, Seattle, WA98104, USA
| | - Andrea Radick
- Division of General Internal Medicine, University of Washington, 325 9th Ave, Seattle, WA98104, USA
| | - Cristina Murray-Krezan
- Department of Medicine, University of Pittsburgh, 200 Meyran Ave., Pittsburgh, PA15213, USA
| | - Kimberly Page
- Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
| | - Alain H Litwin
- Clemson University School of Health Research605 Grove RoadGreenvilleSC29605, USA; Department of Medicine, University of South Carolina School of Medicine, 876 W Faris Rd, Greenville, SC29605, USA; Department of Medicine, Prisma Health, 876 W Faris Rd, Greenville, SC29605, USA
| |
Collapse
|
31
|
D’Onofrio G, Edelman EJ, Hawk KF, Chawarski MC, Pantalon MV, Owens PH, Martel SH, Rothman R, Saheed M, Schwartz RP, Cowan E, Richardson L, Salsitz E, Lyons MS, Freiermuth C, Wilder C, Whiteside L, Tsui JI, Klein JW, Coupet E, O’Connor PG, Matthews AG, Murphy SM, Huntley K, Fiellin DA. Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder. JAMA Netw Open 2023; 6:e235439. [PMID: 37017967 PMCID: PMC10077107 DOI: 10.1001/jamanetworkopen.2023.5439] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Accepted: 02/05/2023] [Indexed: 04/06/2023] Open
Abstract
Importance Emergency department (ED)-initiated buprenorphine for the treatment of opioid use disorder (OUD) is underused. Objective To evaluate whether provision of ED-initiated buprenorphine with referral for OUD increased after implementation facilitation (IF), an educational and implementation strategy. Design, Setting, and Participants This multisite hybrid type 3 effectiveness-implementation nonrandomized trial compared grand rounds with IF, with pre-post 12-month baseline and IF evaluation periods, at 4 academic EDs. The study was conducted from April 1, 2017, to November 30, 2020. Participants were ED and community clinicians treating patients with OUD and observational cohorts of ED patients with untreated OUD. Data were analyzed from July 16, 2021, to July 14, 2022. Exposure A 60-minute in-person grand rounds was compared with IF, a multicomponent facilitation strategy that engaged local champions, developed protocols, and provided learning collaboratives and performance feedback. Main Outcomes and Measures The primary outcomes were the rate of patients in the observational cohorts who received ED-initiated buprenorphine with referral for OUD treatment (primary implementation outcome) and the rate of patients engaged in OUD treatment at 30 days after enrollment (effectiveness outcome). Additional implementation outcomes included the numbers of ED clinicians with an X-waiver to prescribe buprenorphine and ED visits with buprenorphine administered or prescribed and naloxone dispensed or prescribed. Results A total of 394 patients were enrolled during the baseline evaluation period and 362 patients were enrolled during the IF evaluation period across all sites, for a total of 756 patients (540 [71.4%] male; mean [SD] age, 39.3 [11.7] years), with 223 Black patients (29.5%) and 394 White patients (52.1%). The cohort included 420 patients (55.6%) who were unemployed, and 431 patients (57.0%) reported unstable housing. Two patients (0.5%) received ED-initiated buprenorphine during the baseline period, compared with 53 patients (14.6%) during the IF evaluation period (P < .001). Forty patients (10.2%) were engaged with OUD treatment during the baseline period, compared with 59 patients (16.3%) during the IF evaluation period (P = .01). Patients in the IF evaluation period who received ED-initiated buprenorphine were more likely to be in treatment at 30 days (19 of 53 patients [35.8%]) than those who did not 40 of 309 patients (12.9%; P < .001). Additionally, there were increases in the numbers of ED clinicians with an X-waiver (from 11 to 196 clinicians) and ED visits with provision of buprenorphine (from 259 to 1256 visits) and naloxone (from 535 to 1091 visits). Conclusions and Relevance In this multicenter effectiveness-implementation nonrandomized trial, rates of ED-initiated buprenorphine and engagement in OUD treatment were higher in the IF period, especially among patients who received ED-initiated buprenorphine. Trial Registration ClinicalTrials.gov Identifier: NCT03023930.
Collapse
Affiliation(s)
- Gail D’Onofrio
- Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut
- Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
- Yale School of Public Health, New Haven, Connecticut
| | - E. Jennifer Edelman
- Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
| | - Kathryn F. Hawk
- Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut
| | - Marek C. Chawarski
- Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut
- Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut
| | - Michael V. Pantalon
- Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut
| | - Patricia H. Owens
- Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut
| | - Shara H. Martel
- Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut
| | - Richard Rothman
- Department of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Mustapha Saheed
- Department of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | | | - Ethan Cowan
- Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Lynne Richardson
- Institute for Health Equity Research, Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Edwin Salsitz
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Michael S. Lyons
- Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio
- Center for Addiction Research, University of Cincinnati College of Medicine, Cincinnati, Ohio
| | - Caroline Freiermuth
- Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio
- Center for Addiction Research, University of Cincinnati College of Medicine, Cincinnati, Ohio
| | - Christine Wilder
- Center for Addiction Research, University of Cincinnati College of Medicine, Cincinnati, Ohio
- Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, Ohio
| | - Lauren Whiteside
- Department of Emergency Medicine, University of Washington School of Medicine, Seattle
| | - Judith I. Tsui
- Department of Medicine, University of Washington, Seattle
| | - Jared W. Klein
- Department of Medicine, University of Washington, Seattle
| | - Edouard Coupet
- Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut
| | - Patrick G. O’Connor
- Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
| | | | | | | | - David A. Fiellin
- Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut
- Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
- Yale School of Public Health, New Haven, Connecticut
| |
Collapse
|
32
|
Darnton JB, Bhatraju EP, Beima-Sofie K, Michaels A, Hallgren KA, Soth S, Grekin P, Woolworth S, Tsui JI. "Sign Me Up": a qualitative study of video observed therapy (VOT) for patients receiving expedited methadone take-homes during the COVID-19 pandemic. Addict Sci Clin Pract 2023; 18:21. [PMID: 36991506 PMCID: PMC10052285 DOI: 10.1186/s13722-023-00372-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Accepted: 03/13/2023] [Indexed: 03/31/2023] Open
Abstract
BACKGROUND Federal and state regulations require frequent direct observation of methadone ingestion at an Opioid Treatment Program (OTP)-a requirement that creates barriers to patient access. Video observed therapy (VOT) may help to address public health and safety concerns of providing take-home medications while simultaneously reducing barriers to treatment access and long-term retention. Evaluating user experiences with VOT is important for understanding the acceptability of this strategy. METHODS We conducted a qualitative evaluation of a clinical pilot program of VOT via smartphone that was rapidly implemented between April and August 2020 during the COVID-19 pandemic within three opioid treatment programs. In the program, selected patients submitted video recordings of themselves ingesting methadone take-home doses, which were asynchronously reviewed by their counselor. We recruited participating patients and counselors for semi-structured, individual interviews to explore their VOT experiences after program completion. Interviews were audio recorded and transcribed. Transcripts were analyzed using thematic analysis to identify key factors influencing acceptability and the effect of VOT on the treatment experience. RESULTS We interviewed 12 of the 60 patients who participated in the clinical pilot and 3 of the 5 counselors. Overall, patients were enthusiastic about VOT, noting multiple benefits over traditional treatment experiences, including avoiding frequent travel to the clinic. Some noted how this allowed them to better meet recovery goals by avoiding a potentially triggering environment. Most appreciated having increased time to devote to other life priorities, including maintaining consistent employment. Participants described how VOT increased their autonomy, allowed them to keep treatment private, and normalized treatment to align with other medications that do not require in-person dosing. Participants did not describe major usability issues or privacy concerns with submitting videos. Some participants reported feeling disconnected from counselors while others felt more connected. Counselors felt some discomfort in their new role confirming medication ingestion but saw VOT as a useful tool for select patients. CONCLUSIONS VOT may be an acceptable tool to achieve equipoise between lowering barriers to treatment with methadone and protecting the health and safety of patients and their communities.
Collapse
Affiliation(s)
- James B Darnton
- Division of General Internal Medicine, University of Washington, 325 9th Ave, 359780, Seattle, WA, 98195, USA
- Evergreen Treatment Services, Seattle, WA, 98134, USA
| | - Elenore P Bhatraju
- Division of General Internal Medicine, University of Washington, 325 9th Ave, 359780, Seattle, WA, 98195, USA
| | - Kristin Beima-Sofie
- Department of Global Health, University of Washington, Seattle, WA, 98195, USA
| | - Alyssa Michaels
- Division of HIV, ID, and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA, 94110, USA
| | - Kevin A Hallgren
- Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, 98195, USA
| | - Sean Soth
- Evergreen Treatment Services, Seattle, WA, 98134, USA
| | - Paul Grekin
- Evergreen Treatment Services, Seattle, WA, 98134, USA
- Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, 98195, USA
| | | | - Judith I Tsui
- Division of General Internal Medicine, University of Washington, 325 9th Ave, 359780, Seattle, WA, 98195, USA.
| |
Collapse
|
33
|
Nolan S, Fairgrieve C, Dong H, Garrod E, van Heukelom H, Parappilly BP, McLean M, Tsui JI, Samet JH. A Hospital-based Managed Alcohol Program in a Canadian Setting. J Addict Med 2023; 17:190-196. [PMID: 36149000 PMCID: PMC10062701 DOI: 10.1097/adm.0000000000001080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVES A managed alcohol program (MAP) is a harm reduction strategy that provides regularly, witnessed alcohol to individuals with a severe alcohol use disorder. Although community MAPs have positive outcomes, applicability to hospital settings is unknown. This study describes a hospital-based MAP, characterizes its participants, and evaluates outcomes. METHODS A retrospective chart review of MAP participants was conducted at an academic hospital in Vancouver, Canada, between July 2016 and October 2017. Data included demographics, alcohol/substance use, alcohol withdrawal risk, and MAP indication. Outcomes after MAP initiation included the change in mean daily alcohol consumption and liver enzymes. RESULTS Seventeen patients participated in 26 hospital admissions: 76% male, mean age of 54 years, daily consumption prehospitalization of a mean 14 alcohol standard drinks, 59% reported previous nonbeverage alcohol consumption, and 41% participated in a community MAP. Most participants were high risk for severe, complicated alcohol withdrawal and presented in moderate withdrawal. Continuation of community MAP was the most common indication for hospital-based MAP initiation (38%), followed by a history of leaving hospital against medical advice (35%) and hospital illicit alcohol use (15%). Hospital-based MAP resulted in a mean of 5 fewer alcohol standard drinks daily compared with preadmission ( P = 0.002; 95% confidence interval, 2-8) and improvement in liver enzymes, with few adverse events. CONCLUSIONS Participation in a hospital-based MAP may be an effective safe approach to reduce harms for some individuals with severe alcohol use disorder. Further study is needed to understand who benefits most from hospital-MAP and potential benefits/harms following hospital discharge.
Collapse
Affiliation(s)
- Seonaid Nolan
- From the British Columbia Centre on Substance Use, Vancouver, BC, Canada (SN, HD); Department of Medicine, University of British Columbia, St. Paul's Hospital, Vancouver, BC, Canada (SN); Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada (CF); School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (HD); Providence Health Care, St. Paul's Hospital, Vancouver, BC, Canada (EG, HvH, BPP); Department of Family Medicine, University of British Columbia, St. Paul's Hospital, Vancouver, BC, Canada (MM); Section of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Harborview Medicine Center, Seattle, WA (JIT); and Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA (JHS)
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Lyons MS, Chawarski MC, Rothman R, Whiteside L, Cowan E, Richardson LD, Hawk K, Tsui JI, Schwartz RP, O’Connor P, D’Onofrio G, Fiellin DA, Edelman EJ. Missed Opportunities for HIV and Hepatitis C Screening Among Emergency Department Patients With Untreated Opioid Use Disorder. J Addict Med 2023; 17:210-214. [PMID: 36170184 PMCID: PMC10023471 DOI: 10.1097/adm.0000000000001074] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE We assessed the frequency of emergency department (ED) HIV and hepatitis C (HCV) screening in a high-risk cohort of ED patients with untreated opioid use disorder (OUD). METHODS This analysis used data from a prospective, observational study of English-speaking adults with untreated OUD enrolled from April 2017 to December 2018 in 4 urban, academic EDs. Two cohorts were defined for this analysis by self-reported negative/unknown status for HIV (cohort 1) and HCV (cohort 2). Sites featured structured screening programs throughout the entire enrollment period for HIV and during at least part of the enrollment period for HCV. We calculated the proportion tested for HIV and HCV during the study enrollment ED visit. RESULTS Among 394 evaluated ED patients, 328 of 394 (83.2%) were not tested for HIV or HCV and 244 of 393 (62.1%) lacked a usual medical care provider. In cohort 1, 375 reported negative or unknown HIV status; 59/375 (15.7%) overall and 33/218 (15.1%) of those reporting recent injection drug use were tested for HIV. In cohort 2, 231 reported negative of unknown HCV status; 22/231 (9.5%) overall and 9/98 (9.2%) of those reporting recent injection drug use were tested for HCV. The proportion tested by the ED ranged from 3% to 25% for HIV and 4% to 32% for HCV across study sites. CONCLUSIONS Emergency department HIV and HCV screening remains infrequent among patients with untreated OUD, including those who inject drugs, even in EDs committed to screening. Targeted HIV/HCV screening should be considered as an adjunct strategy until the ideal of universal screening is more fully achieved.
Collapse
Affiliation(s)
- Michael S. Lyons
- Department of Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA
- Center for Addiction Research, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Marek C. Chawarski
- Department of Emergency Medicine, Yale School of Medicine, New Haven, CT, USA
- Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA
| | - Richard Rothman
- Department of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Lauren Whiteside
- Department of Emergency Medicine, University of Washington School of Medicine Seattle WA USA
| | - Ethan Cowan
- Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, NY, NY, USA
| | - Lynne D. Richardson
- Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, NY, NY, USA
- Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, NY, NY, USA
| | - Kathryn Hawk
- Department of Emergency Medicine, Yale School of Medicine, New Haven, CT, USA
| | - Judith I. Tsui
- Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA
| | | | - Patrick O’Connor
- Program in Addiction Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
| | - Gail D’Onofrio
- Department of Emergency Medicine, Yale School of Medicine, New Haven, CT, USA
| | - David A. Fiellin
- Department of Emergency Medicine, Yale School of Medicine, New Haven, CT, USA
- Program in Addiction Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
- Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT, USA
| | - E. Jennifer Edelman
- Program in Addiction Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
- Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT, USA
| |
Collapse
|
35
|
Cook RR, Foot C, Arah OA, Humphreys K, Rudolph KE, Luo SX, Tsui JI, Levander XA, Korthuis PT. Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations. Addict Sci Clin Pract 2023; 18:11. [PMID: 36788634 PMCID: PMC9930351 DOI: 10.1186/s13722-023-00364-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Accepted: 02/01/2023] [Indexed: 02/16/2023] Open
Abstract
BACKGROUND Co-use of stimulants and opioids is rapidly increasing. Randomized clinical trials (RCTs) have established the efficacy of medications for opioid use disorder (MOUD), but stimulant use may decrease the likelihood of initiating MOUD treatment. Furthermore, trial participants may not represent "real-world" populations who would benefit from treatment. METHODS We conducted a two-stage analysis. First, associations between stimulant use (time-varying urine drug screens for cocaine, methamphetamine, or amphetamines) and initiation of buprenorphine or extended-release naltrexone (XR-NTX) were estimated across two RCTs (CTN-0051 X:BOT and CTN-0067 CHOICES) using adjusted Cox regression models. Second, results were generalized to three target populations who would benefit from MOUD: Housed adults identifying the need for OUD treatment, as characterized by the National Survey on Drug Use and Health (NSDUH); adults entering OUD treatment, as characterized by Treatment Episodes Dataset (TEDS); and adults living in rural regions of the U.S. with high rates of injection drug use, as characterized by the Rural Opioids Initiative (ROI). Generalizability analyses adjusted for differences in demographic characteristics, substance use, housing status, and depression between RCT and target populations using inverse probability of selection weighting. RESULTS Analyses included 673 clinical trial participants, 139 NSDUH respondents (weighted to represent 661,650 people), 71,751 TEDS treatment episodes, and 1,933 ROI participants. The majority were aged 30-49 years, male, and non-Hispanic White. In RCTs, stimulant use reduced the likelihood of MOUD initiation by 32% (adjusted HR [aHR] = 0.68, 95% CI 0.49-0.94, p = 0.019). Stimulant use associations were slightly attenuated and non-significant among housed adults needing treatment (25% reduction, aHR = 0.75, 0.48-1.18, p = 0.215) and adults entering OUD treatment (28% reduction, aHR = 0.72, 0.51-1.01, p = 0.061). The association was more pronounced, but still non-significant among rural people injecting drugs (39% reduction, aHR = 0.61, 0.35-1.06, p = 0.081). Stimulant use had a larger negative impact on XR-NTX initiation compared to buprenorphine, especially in the rural population (76% reduction, aHR = 0.24, 0.08-0.69, p = 0.008). CONCLUSIONS Stimulant use is a barrier to buprenorphine or XR-NTX initiation in clinical trials and real-world populations that would benefit from OUD treatment. Interventions to address stimulant use among patients with OUD are urgently needed, especially among rural people injecting drugs, who already suffer from limited access to MOUD.
Collapse
Affiliation(s)
- R R Cook
- Section of Addiction Medicine, Department of Medicine, Oregon Health & Science University, Sam Jackson Hall, Suite 3370, 3245 SW Pavilion Loop, Portland, OR, 97239, USA.
| | - C Foot
- Section of Addiction Medicine, Department of Medicine, Oregon Health & Science University, Sam Jackson Hall, Suite 3370, 3245 SW Pavilion Loop, Portland, OR, 97239, USA
| | - O A Arah
- Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles (UCLA), Los Angeles, CA, USA
- Division of Physical Sciences, Department of Statistics, UCLA College, Los Angeles, CA, USA
- Research Unit for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark
| | - K Humphreys
- Center for Innovation to Implementation, VA Palo Alto Health Care System, Palo Alto, CA, USA
- Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, CA, USA
| | - K E Rudolph
- Department of Epidemiology, School of Public Health, Columbia University, New York, NY, USA
| | - S X Luo
- Division on Substance Use Disorders, Department of Psychiatry, Columbia University, New York, USA
| | - J I Tsui
- Department of Medicine, University of Washington, Seattle, WA, USA
| | - X A Levander
- Section of Addiction Medicine, Department of Medicine, Oregon Health & Science University, Sam Jackson Hall, Suite 3370, 3245 SW Pavilion Loop, Portland, OR, 97239, USA
| | - P T Korthuis
- Section of Addiction Medicine, Department of Medicine, Oregon Health & Science University, Sam Jackson Hall, Suite 3370, 3245 SW Pavilion Loop, Portland, OR, 97239, USA
| |
Collapse
|
36
|
Levander XA, Foot CA, Magnusson SL, Cook RR, Ezell JM, Feinberg J, Go VF, Lancaster KE, Salisbury-Afshar E, Smith GS, Westergaard RP, Young AM, Tsui JI, Korthuis PT. Contraception and Healthcare Utilization by Reproductive-Age Women Who Use Drugs in Rural Communities: a Cross-Sectional Survey. J Gen Intern Med 2023; 38:98-106. [PMID: 35731368 PMCID: PMC9849531 DOI: 10.1007/s11606-022-07558-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Accepted: 03/30/2022] [Indexed: 01/22/2023]
Abstract
BACKGROUND Women who use drugs (WWUD) have low rates of contraceptive use and high rates of unintended pregnancy. Drug use is common among women in rural U.S. communities, with limited data on how they utilize reproductive, substance use disorder (SUD), and healthcare services. OBJECTIVE We determined contraceptive use prevalence among WWUD in rural communities then compared estimates to women from similar rural areas. We investigated characteristics of those using contraceptives, and associations between contraceptive use and SUD treatment, healthcare utilization, and substance use. DESIGN Rural Opioids Initiative (ROI) - cross-sectional survey using respondent-driven sampling (RDS) involving eight rural U.S. regions (January 2018-March 2020); National Survey on Family Growth (NSFG) - nationally-representative U.S. household reproductive health survey (2017-2019). PARTICIPANTS Women aged 18-49 with prior 30-day non-prescribed opioid and/or non-opioid injection drug use; fecundity determined by self-reported survey responses. MAIN MEASURES Unweighted and RDS-weighted prevalence estimates of medical/procedural contraceptive use; chi-squared tests and multi-level linear regressions to test associations. KEY RESULTS Of 855 women in the ROI, 36.8% (95% CI 33.7-40.1, unweighted) and 38.6% (95% CI 30.7-47.2, weighted) reported contraceptive use, compared to 66% of rural women in the NSFG sample. Among the ROI women, 27% had received prior 30-day SUD treatment via outpatient counseling or inpatient program and these women had increased odds of contraceptive use (aOR 1.50 [95% CI 1.08-2.06]). There was a positive association between contraception use and recent medications for opioid use disorder (aOR 1.34 [95% CI 0.95-1.88]) and prior 6-month primary care utilization (aOR 1.32 [95% CI 0.96-1.82]) that did not meet the threshold for statistical significance. CONCLUSION WWUD in rural areas reported low contraceptive use; those who recently received SUD treatment had greater odds of contraceptive use. Improvements are needed in expanding reproductive and preventive health within SUD treatment and primary care services in rural communities.
Collapse
Affiliation(s)
- Ximena A Levander
- Division of General Internal Medicine & Geriatrics, Addiction Medicine Section, Department of Medicine, Oregon Health & Science University, Portland, OR, USA.
| | - Canyon A Foot
- Division of General Internal Medicine & Geriatrics, Addiction Medicine Section, Department of Medicine, Oregon Health & Science University, Portland, OR, USA
| | | | - Ryan R Cook
- Division of General Internal Medicine & Geriatrics, Addiction Medicine Section, Department of Medicine, Oregon Health & Science University, Portland, OR, USA
| | - Jerel M Ezell
- Africana Studies and Research Center, Cornell Center for Health Equity, Cornell University, Ithaca, NY, USA
| | - Judith Feinberg
- Department of Behavioral Medicine and Psychiatry, West Virginia University, Morgantown, WV, USA
- Department of Medicine Section of Infectious Diseases, West Virginia University, Morgantown, WV, USA
| | - Vivian F Go
- Department of Health Behavior, School of Global Public Health, University of North Carolina - Chapel Hill, Chapel Hill, NC, USA
| | - Kathryn E Lancaster
- Division of Epidemiology, College of Public Health, Ohio State University, Columbus, OH, USA
| | | | - Gordon S Smith
- Department of Epidemiology and Biostatistics, School of Public Health, West Virginia University, Morgantown, WV, USA
| | - Ryan P Westergaard
- Division of Infectious Diseases, Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA
| | - April M Young
- Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY, USA
- Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY, USA
| | - Judith I Tsui
- Department of Medicine, Division of General Internal Medicine, University of Washington, Seattle, WA, USA
| | - P Todd Korthuis
- Division of General Internal Medicine & Geriatrics, Addiction Medicine Section, Department of Medicine, Oregon Health & Science University, Portland, OR, USA
| |
Collapse
|
37
|
Austin EJ, Gojic AJ, Bhatraju EP, Pierce KA, Pickering EI, Tung EL, Scott JD, Hansen RN, Glick SN, Stekler JD, Connolly NC, Villafuerte S, McPadden M, Deutsch S, Ninburg M, Kubiniec R, Williams EC, Tsui JI. Barriers and facilitators to implementing a Pharmacist, Physician, and Patient Navigator-Collaborative Care Model (PPP-CCM) to treat hepatitis C among people who inject drugs. Int J Drug Policy 2023; 111:103924. [PMID: 36521197 PMCID: PMC9868078 DOI: 10.1016/j.drugpo.2022.103924] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2022] [Revised: 11/21/2022] [Accepted: 11/26/2022] [Indexed: 12/15/2022]
Abstract
BACKGROUND Direct-acting antivirals (DAAs) offer an unprecedented opportunity to eliminate hepatitis C virus (HCV) infection, yet barriers among people who inject drugs (PWID) remain. Having pharmacists provide care through collaborative drug therapy agreements (CDTAs) offers a promising solution. We developed and piloted a Pharmacist, Physician, and Patient Navigator-Collaborative Care Model (PPP-CCM) which utilized pharmacists to directly deliver HCV care at community organizations serving PWID. We conducted formative evaluation of the PPP-CCM pilot to characterize implementation experiences. METHODS The PPP-CCM was implemented from November of 2020 through July of 2022. Formative evaluation team members observed implementation-related meetings and conducted multiple site visits, taking detailed fieldnotes. Fieldnotes were iteratively reviewed to identify barriers and facilitators to implementation and used to inform 7 key informant interviews conducted with programmatic staff at the end of the pilot. All data were analyzed using a Rapid Assessment Process (RAP) guided by the Consolidated Framework for Implementation Research (CFIR). The formative evaluation team shared results with program stakeholders (pharmacists, physicians, and other site staff) to verify and expand on learnings. RESULTS Evaluation of PPP-CCM revealed 5 themes, encompassing all CFIR domains: 1) PPP-CCM was feasible but challenging to deliver efficiently; 2) the pharmacist role and characteristics (e.g., being flexible, available, and patient-centered) were key to PPP-CCM successes; 3) the PPP-CCM team met challenges engaging patients over time, but some team-based strategies helped; 4) community site characteristics (e.g., existing trusting relationships with PWID and physical space that enabled program visibility) were important contributors; and 5) financial barriers may limit PPP-CCM scale-up and sustainability. CONCLUSION PPP-CCM is a novel and promising approach to HCV care delivery for PWID who may previously lack engagement in traditional care models, but careful attention needs to be paid to financial barriers to ensure scalability and sustainability.
Collapse
Affiliation(s)
- Elizabeth J Austin
- Department of Health Systems and Population Health, University of Washington, Seattle WA, United States.
| | - Alexander J Gojic
- Department of Medicine, Division of General Internal Medicine University of Washington, Seattle WA, United States
| | - Elenore P Bhatraju
- Department of Medicine, Division of General Internal Medicine University of Washington, Seattle WA, United States
| | - Kathleen A Pierce
- Department of Pharmacy, University of Washington, Seattle WA, United States; Kelley-Ross Pharmacy Group, Seattle WA, United States
| | - Eleanor I Pickering
- Department of Social and Behavioral Sciences, Yale School of Public Health, United States
| | - Elyse L Tung
- Department of Pharmacy, University of Washington, Seattle WA, United States; Kelley-Ross Pharmacy Group, Seattle WA, United States
| | - John D Scott
- Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle WA, United States
| | - Ryan N Hansen
- Department of Pharmacy, University of Washington, Seattle WA, United States; Kelley-Ross Pharmacy Group, Seattle WA, United States
| | - Sara N Glick
- Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle WA, United States; HIV/STD Program, Public Health - Seattle & King County, Seattle WA, United States
| | - Joanne D Stekler
- Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle WA, United States
| | - Nancy C Connolly
- Department of Medicine, Division of General Internal Medicine University of Washington, Seattle WA, United States
| | - Sarah Villafuerte
- Hepatitis Education Project, Seattle WA, United States (affiliation at the time of research)
| | - Madison McPadden
- Hepatitis Education Project, Seattle WA, United States (affiliation at the time of research)
| | - Sarah Deutsch
- Hepatitis Education Project, Seattle WA, United States (affiliation at the time of research)
| | - Michael Ninburg
- Hepatitis Education Project, Seattle WA, United States (affiliation at the time of research)
| | | | - Emily C Williams
- Department of Health Systems and Population Health, University of Washington, Seattle WA, United States; Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care, Health Services Research & Development, VA Puget Sound, Seattle WA, United States
| | - Judith I Tsui
- Department of Medicine, Division of General Internal Medicine University of Washington, Seattle WA, United States
| |
Collapse
|
38
|
James JR, Tsui JI. Training Providers of People Who Use Drugs to Offer Hepatitis C Treatment: A Washington State Initiative. Subst Abus 2023; 44:86-90. [PMID: 37226904 DOI: 10.1177/08897077231167047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
To address hepatitis C infection (HCV) treatment gaps among people who use drugs (PWUD), a statewide initiative trained buprenorphine waiver trainers to offer an optional HCV treatment module to waiver trainees. Five of twelve trained buprenorphine trainers went on to conduct HCV sessions at waiver trainings, reaching 57 trainees. Word-of-mouth led to multiple additional presentations by the project team, suggesting an unmet need for more education about treating HCV among PWUD. A post-session survey suggested that participant views on the importance of treating HCV among PWUD changed and that almost all felt confident to treat uncomplicated HCV. While limitations of this evaluation include that no baseline survey was conducted and that the survey response rate was low, findings suggest that among providers who care for PWUD, limited training may be adequate to change views about treating HCV. Future research is needed to explore models of care that will support providers to prescribe lifesaving direct-acting antiviral medications to PWUD with HCV.
Collapse
Affiliation(s)
- Jocelyn R James
- Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA, USA
| | - Judith I Tsui
- Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA, USA
| |
Collapse
|
39
|
Dombrowski JC, Halliday S, Tsui JI, Rao D, Sherr K, Ramchandani MS, Emerson R, Fleming M, Wood T, Chwastiak L. Adaptation of the collaborative care model to integrate behavioral health care into a low-barrier HIV clinic. Implement Res Pract 2023; 4:26334895231167105. [PMID: 37790178 PMCID: PMC10123894 DOI: 10.1177/26334895231167105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/05/2023] Open
Abstract
Background The collaborative care management (CoCM) model is an evidence-based intervention for integrating behavioral health care into nonpsychiatric settings. CoCM has been extensively studied in primary care clinics, but implementation in nonconventional clinics, such as those tailored to provide care for high-need, complex patients, has not been well described. Method We adapted CoCM for a low-barrier HIV clinic that provides walk-in medical care for a patient population with high levels of mental illness, substance use, and housing instability. The Exploration, Preparation, Implementation, and Sustainment model guided implementation activities and support through the phases of implementing CoCM. The Framework for Reporting Adaptations and Modifications to Evidence-Based Interventions guided our documentation of adaptations to process-of-care elements and structural elements of CoCM. We used a multicomponent strategy to implement the adapted CoCM model. In this article, we describe our experience through the first 6 months of implementation. Results The key contextual factors necessitating adaptation of the CoCM model were the clinic team structure, lack of scheduled appointments, high complexity of the patient population, and time constraints with competing priorities for patient care, all of which required substantial flexibility in the model. The process-of-care elements were adapted to improve the fit of the intervention with the context, but the core structural elements of CoCM were maintained. Conclusions The CoCM model can be adapted for a setting that requires more flexibility than the usual primary care clinic while maintaining the core elements of the intervention.
Collapse
Affiliation(s)
- Julia C. Dombrowski
- Department of Medicine, University of Washington, Seattle, WA, USA
- Department of Epidemiology, University of Washington, Seattle, WA, USA
- Public Health – Seattle & King County, HIV/STD Program, Seattle, WA, USA
| | - Scott Halliday
- Department of Global Health, University of Washington, Seattle, WA, USA
| | - Judith I. Tsui
- Department of Medicine, University of Washington, Seattle, WA, USA
| | - Deepa Rao
- Department of Global Health, University of Washington, Seattle, WA, USA
- Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
| | - Kenneth Sherr
- Department of Epidemiology, University of Washington, Seattle, WA, USA
- Department of Global Health, University of Washington, Seattle, WA, USA
- Department of Industrial & Systems Engineering, University of Washington, Seattle, WA, USA
| | - Meena S. Ramchandani
- Department of Medicine, University of Washington, Seattle, WA, USA
- Public Health – Seattle & King County, HIV/STD Program, Seattle, WA, USA
| | - Ramona Emerson
- Department of Medicine, University of Washington, Seattle, WA, USA
| | - Mark Fleming
- Public Health – Seattle & King County, HIV/STD Program, Seattle, WA, USA
| | - Teagan Wood
- Department of Social Work, Harborview Medical Center, Seattle, WA, USA
| | - Lydia Chwastiak
- Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
| |
Collapse
|
40
|
Braciszewski JM, Idu AE, Yarborough BJH, Stumbo SP, Bobb JF, Bradley KA, Rossom RC, Murphy MT, Binswanger IA, Campbell CI, Glass JE, Matson TE, Lapham GT, Loree AM, Barbosa-Leiker C, Hatch MA, Tsui JI, Arnsten JH, Stotts A, Horigian V, Hutcheson R, Bart G, Saxon AJ, Thakral M, Ling Grant D, Pflugeisen CM, Usaga I, Madziwa LT, Silva A, Boudreau DM. Sex Differences in Comorbid Mental and Substance Use Disorders Among Primary Care Patients With Opioid Use Disorder. Psychiatr Serv 2022; 73:1330-1337. [PMID: 35707859 PMCID: PMC9722542 DOI: 10.1176/appi.ps.202100665] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
OBJECTIVE The authors sought to characterize the 3-year prevalence of mental disorders and nonnicotine substance use disorders among male and female primary care patients with documented opioid use disorder across large U.S. health systems. METHODS This retrospective study used 2014-2016 data from patients ages ≥16 years in six health systems. Diagnoses were obtained from electronic health records or claims data; opioid use disorder treatment with buprenorphine or injectable extended-release naltrexone was determined through prescription and procedure data. Adjusted prevalence of comorbid conditions among patients with opioid use disorder (with or without treatment), stratified by sex, was estimated by fitting logistic regression models for each condition and applying marginal standardization. RESULTS Females (53.2%, N=7,431) and males (46.8%, N=6,548) had a similar prevalence of opioid use disorder. Comorbid mental disorders among those with opioid use disorder were more prevalent among females (86.4% vs. 74.3%, respectively), whereas comorbid other substance use disorders (excluding nicotine) were more common among males (51.9% vs. 60.9%, respectively). These differences held for those receiving medication treatment for opioid use disorder, with mental disorders being more common among treated females (83% vs. 71%) and other substance use disorders more common among treated males (68% vs. 63%). Among patients with a single mental health condition comorbid with opioid use disorder, females were less likely than males to receive medication treatment for opioid use disorder (15% vs. 20%, respectively). CONCLUSIONS The high rate of comorbid conditions among patients with opioid use disorder indicates a strong need to supply primary care providers with adequate resources for integrated opioid use disorder treatment.
Collapse
Affiliation(s)
- Jordan M Braciszewski
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Abisola E Idu
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Bobbi Jo H Yarborough
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Scott P Stumbo
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Jennifer F Bobb
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Katharine A Bradley
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Rebecca C Rossom
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Mark T Murphy
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Ingrid A Binswanger
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Cynthia I Campbell
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Joseph E Glass
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Theresa E Matson
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Gwen T Lapham
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Amy M Loree
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Celestina Barbosa-Leiker
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Mary A Hatch
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Judith I Tsui
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Julia H Arnsten
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Angela Stotts
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Viviana Horigian
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Rebecca Hutcheson
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Gavin Bart
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Andrew J Saxon
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Manu Thakral
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Deborah Ling Grant
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Chaya Mangel Pflugeisen
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Ingrid Usaga
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Lawrence T Madziwa
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Angela Silva
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| | - Denise M Boudreau
- Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit (Braciszewski, Loree); Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle (Idu, Bobb, Bradley, Glass, Matson, Lapham, Madziwa); Kaiser Permanente Northwest Center for Health Research, Portland, Oregon (Yarborough, Stumbo); HealthPartners Institute and Department of Research, University of Minnesota, Minneapolis (Rossom); MultiCare Institute for Research and Innovation, MultiCare Health System, Tacoma, Washington (Murphy, Pflugeisen, Silva); Kaiser Permanente Colorado Institute for Health Research, Colorado Permanente Medical Group, Department of Health System Science, Bernard J. Tyson Kaiser Permanente School of Medicine, University of Colorado School of Medicine, Aurora (Binswanger); Kaiser Permanente Northern California Division of Research, Oakland (Campbell); Department of Health Systems and Population Health, University of Washington, Seattle (Lapham, Hutcheson); Washington State University Health Sciences Spokane, Spokane (Barbosa-Leiker); Department of Psychiatry and Behavioral Sciences and Addictions, Drug and Alcohol Institute, University of Washington, Seattle (Hatch); Department of Medicine, University of Washington and Harborview Medical Center, Seattle (Tsui); Albert Einstein College of Medicine, Montefiore Medical Center, New York City (Arnsten); Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston (Stotts); Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami (Horigian, Usaga); Hennepin Healthcare and Department of Medicine, University of Minnesota Medical School, Minneapolis (Bart); Veterans Affairs Puget Sound Health Care System, Seattle (Saxon); Manning College of Nursing and Health Sciences, University of Massachusetts, Boston (Thakral); Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena (Ling Grant); Genentech, Inc., San Francisco (Boudreau)
| |
Collapse
|
41
|
Hallgren KA, Darnton J, Soth S, Blalock KL, Michaels A, Grekin P, Saxon AJ, Woolworth S, Tsui JI. Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic. J Subst Abuse Treat 2022; 143:108896. [PMID: 36215911 PMCID: PMC9531364 DOI: 10.1016/j.jsat.2022.108896] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 05/20/2022] [Accepted: 09/29/2022] [Indexed: 11/07/2022]
Abstract
BACKGROUND Methadone is one of the most utilized treatments for opioid use disorder. However, requirements for observing methadone dosing can impose barriers to patients and increase risk for respiratory illness transmission (e.g., COVID-19). Video observation of methadone dosing at home could allow opioid treatment programs (OTPs) to offer more take-home doses while ensuring patient safety through remote observation of ingestion. METHODS Between April and August 2020, a clinical pilot program of video observation of methadone take-home dosing via smartphone was conducted within a multisite OTP agency. Participating patients completed a COVID-19 symptom screener and submitted video recordings of themselves ingesting all methadone take-home doses. Patients who followed these procedures for a two-week trial period could continue participating in the full pilot program and potentially receive more take-home doses. This retrospective observational study characterizes patient engagement and compares clinical outcomes with matched controls. RESULTS Of 44 patients who initiated the two-week trial, 33 (75 %) were successful and continued participating in the full pilot program. Twenty full pilot participants (61 %) received increased take-home doses. Full pilot participants had more days with observed dosing over a 60-day period than matched controls (mean = 53.2 vs. 16.6 days, respectively). Clinical outcomes were similar between pilot participants and matched controls. CONCLUSIONS Video observation of methadone take-home dosing implemented during the COVID-19 pandemic was feasible. This model has the potential to enhance safety by increasing rates of observed methadone dosing and reducing infection risks and barriers associated with relying solely on face-to-face observation of methadone dosing.
Collapse
Affiliation(s)
- Kevin A. Hallgren
- University of Washington School of Medicine, Department of Psychiatry and Behavioral Sciences, Seattle, WA 98195, United States,Corresponding author at: Behavioral Research in Technology and Engineering Center, Department of Psychiatry and Behavioral Sciences, University of Washington Medical Center, Box 356560, 1959 NE Pacific St., Seattle, WA 98195, United States
| | - James Darnton
- University of Washington, Division of General Internal Medicine, Seattle, WA 98195, United States,Evergreen Treatment Services, Seattle, WA 98134, United States
| | - Sean Soth
- Evergreen Treatment Services, Seattle, WA 98134, United States
| | - Kendra L. Blalock
- University of Washington, Division of General Internal Medicine, Seattle, WA 98195, United States
| | - Alyssa Michaels
- University of Washington, Division of General Internal Medicine, Seattle, WA 98195, United States
| | - Paul Grekin
- University of Washington School of Medicine, Department of Psychiatry and Behavioral Sciences, Seattle, WA 98195, United States,Evergreen Treatment Services, Seattle, WA 98134, United States
| | - Andrew J. Saxon
- University of Washington School of Medicine, Department of Psychiatry and Behavioral Sciences, Seattle, WA 98195, United States,Center of Excellence in Substance Addiction Treatment and Education (CESATE), VA Puget Sound Health Care System, Seattle, WA 98108, United States
| | - Steve Woolworth
- Evergreen Treatment Services, Seattle, WA 98134, United States
| | - Judith I. Tsui
- University of Washington, Division of General Internal Medicine, Seattle, WA 98195, United States
| |
Collapse
|
42
|
Jack HE, Denisiuk ED, Collins BA, Stephens D, Blalock KL, Klein JW, Bhatraju EP, Merrill JO, Hallgren KA, Tsui JI. Peer providers and linkage with buprenorphine care after hospitalization: A retrospective cohort study. Subst Abus 2022; 43:1308-1316. [PMID: 35896006 PMCID: PMC9586121 DOI: 10.1080/08897077.2022.2095078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
Background: People with opioid use disorder (OUD) are increasingly started on buprenorphine in the hospital, yet many patients do not attend outpatient buprenorphine care after discharge. Peer providers, people in recovery themselves, are a growing part of addiction care. We examine whether patients who received a low-intensity, peer-delivered intervention during hospitalization had a greater rate of linking with outpatient buprenorphine care relative to those not seen by a peer. Methods: This was a retrospective cohort study of adults with OUD who were started on buprenorphine during hospitalization. The primary outcome was receipt of a buprenorphine prescription within 30 days of discharge. Secondary outcomes included attendance at a follow-up visit with a buprenorphine provider within 30 days and hospital readmission within 90 days. Modified Poisson regression analyses tested for differences in the rate ratios (RR) of each binary outcome for patients who were versus were not seen by a peer provider. Peer notes in the electronic health record were reviewed to characterize peer activities. Results: 111 patients met the study inclusion criteria, 31.5% of whom saw a peer provider. 55.0% received a buprenorphine prescription within 30 days of hospital discharge. Patients with versus without peer provider encounters did not significantly differ in the rates of receiving a buprenorphine prescription (RR = 1.06, 95% CI: 0.74-1.51), hospital readmission (RR = 1.45, 95% CI: 0.80-2.64), or attendance at a buprenorphine follow-up visit (RR = 1.03, 95% CI: 0.68-1.57). Peers most often listened to or shared experiences with patients (68.6% of encounters) and helped facilitate medical care (60.0% of encounters). Conclusions: There were no differences in multiple measures of buprenorphine follow-up between patients who received this low-intensity peer intervention and those who did not. There is need to investigate what elements of peer provider programs contribute to patient outcomes and what outcomes should be assessed when evaluating peer programs.
Collapse
Affiliation(s)
- Helen E. Jack
- Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA
| | - Eric D. Denisiuk
- School of Medicine, University of Washington, Seattle, Washington, USA
| | - Brett A. Collins
- School of Medicine, University of Washington, Seattle, Washington, USA
| | - Dan Stephens
- School of Medicine, University of Washington, Seattle, Washington, USA
| | - Kendra L. Blalock
- Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA
| | - Jared W. Klein
- Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA
| | - Elenore P. Bhatraju
- Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA
| | - Joseph O. Merrill
- Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA
| | - Kevin A. Hallgren
- Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA
| | - Judith I. Tsui
- Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA
| |
Collapse
|
43
|
Litwin AH, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, Kim AY, Norton BL, Heo M, Arnsten J, Meissner P, Karasz A, Mckee MD, Ward JW, Johnson N, Pericot-Valverde I, Agyemang L, Stein ES, Thomas A, Borsuk C, Blalock KL, Wilkinson S, Wagner K, Roche J, Murray-Krezan C, Anderson J, Jacobsohn V, Luetkemeyer AF, Falade-Nwulia O, Page K. Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial. Lancet Gastroenterol Hepatol 2022; 7:1112-1127. [PMID: 36370741 DOI: 10.1016/s2468-1253(22)00275-8] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Revised: 08/11/2022] [Accepted: 08/12/2022] [Indexed: 11/11/2022]
Abstract
BACKGROUND To achieve WHO targets for the elimination of hepatitis C virus (HCV) as a public threat, an increased uptake of HCV treatment among people who inject drugs (PWID) is urgently needed. Optimal HCV co-located treatment models for PWID have not yet been identified. We aimed to compare two patient-centred models of HCV care in PWID with active drug use. METHODS We did a pragmatic randomised controlled trial at eight US cities in eight opioid treatment programmes and 15 community health centres. PWID actively injecting within 90 days of study entry were randomly assigned (1:1) to either patient navigation or modified directly observed therapy (mDOT) using computer-generated variable block sizes of 2-6 stratified by city, clinical settings, and cirrhosis status. The randomisation code was concealed, in a centralised REDCap database platform, from all investigators and research staff except for an authorised data manager at the data coordinating centre. All participants received a fixed-dose combination tablet (sofosbuvir 400 mg plus velpatasvir 100 mg) orally once daily for 12 weeks. The primary outcome was sustained virological response (SVR; determined by chart review between 70 days and 365 days after end of treatment and if unavailable, by study blood draws), and secondary outcomes were treatment initiation, adherence (measured by electronic blister packs), and treatment completion. Analyses were conducted within the modified intention-to-treat (mITT; all who initiated treatment), intention-to-treat (all who were randomised), and per-protocol populations. This trial is registered with ClinicalTrials.gov, NCT02824640. FINDINGS Between Sept 15, 2016, and Aug 14, 2018, 1891 individuals were screened and 1136 were excluded (213 declined to participate and 923 did not meet the eligibility criteria). We randomly assigned 755 participants to patient navigation (n=379) or mDOT (n=376). In the mITT sample of participants who were randomised and initiated treatment (n=623), 226 (74% [95% CI 69-79]) of 306 participants in the mDOT group and 236 (76% [69-79]) of 317 in the patient navigation group had an SVR, with no significant difference between the groups (adjusted odds ratio [AOR] 0·97 [95% CI 0·66-1·42]; p=0·35). In the ITT sample (n=755), 226 (60% [95% CI 55-65]) of 376 participants in the mDOT group and 236 (62% [57-67]) of 379 in the patient navigation group had an SVR (AOR 0·92 [0·68-1·25]; p=0·61) and in the per-protocol sample (n=501), 226 (91% [87-94]) of 248 participants in the mDOT group and 235 (93% [89-96]) of 253 in the patient navigation group had an SVR (AOR 0·79 [0·41-1·55]; p=0·44). 306 (81%) of 376 participants in the mDOT group and 317 (84%) of 379 participants in the patient navigation group initiated treatment (AOR 0·86 [0·58-1·26]; p=0·44) and, among those, 251 (82%) participants in the mDOT group and 264 (83%) participants in the patient navigation group completed treatment (AOR 0·90 [0·58-1·39]; p=0·63). Mean daily adherence was higher in the mDOT group (78% [95% CI 75-81]) versus the patient navigation group (73% [70-77]), with a difference of 4·7% ([1·9-7·4]; p=0·0010). 421 serious adverse events were reported (217 in the mDOT group and 204 in the patient navigation group), with the most common being hospital admission (176 in the mDOT group vs 161 in the patient navigation group). INTERPRETATION In this trial of active PWID, both models resulted in high SVR. Although adherence was significantly higher in the mDOT group versus the patient navigation group, there was no significant difference in SVR between the groups. Increases in adherence and treatment completion were associated with an increased likelihood of SVR. These results suggest that active PWID can reach high SVRs in diverse settings with either mDOT or patient navigation support. FUNDING Patient-Centered Outcomes Research Institute, Gilead Sciences, Quest Diagnostics, Monogram Biosciences, and OraSure Technologies.
Collapse
Affiliation(s)
- Alain H Litwin
- School of Health Research, Clemson University, Clemson, SC, USA; Department of Medicine, University of South Carolina School of Medicine, Greenville, SC, USA; Department of Medicine, Prisma Health, Greenville, SC, USA.
| | - Paula J Lum
- Department of Medicine, University of California San Francisco, San Francisco, CA, USA
| | - Lynn E Taylor
- College of Pharmacy, University of Rhode Island, Providence, RI, USA; HIV and Viral Hepatitis Services, CODAC Behavioral Health, Providence, RI, USA
| | - Shruti H Mehta
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | - Judith I Tsui
- Department of Medicine, University of Washington, Seattle, WA, USA
| | - Judith Feinberg
- Department of Behavioral Medicine and Psychiatry, and Department of Medicine, Section of Infectious Diseases, West Virginia University School of Medicine, Morgantown, WV, USA
| | - Arthur Y Kim
- Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Brianna L Norton
- Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, USA
| | - Moonseong Heo
- Department of Public Health Sciences, Clemson University, Clemson, SC, USA
| | - Julia Arnsten
- Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, USA
| | - Paul Meissner
- Department of Family and Social Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, USA
| | - Alison Karasz
- Department of Family Medicine & Community Health, University of Massachusetts Chan Medical School, Worcester, MA, USA
| | - M Diane Mckee
- Department of Family Medicine & Community Health, University of Massachusetts Chan Medical School, Worcester, MA, USA
| | - John W Ward
- Coalition for Global Hepatitis Elimination, The Task Force for Global Health, Decatur, GA, USA
| | - Nirah Johnson
- New York City Department of Health and Mental Hygiene, New York City, NY, USA
| | - Irene Pericot-Valverde
- Department of Psychology, Clemson University, Clemson, SC, USA; School of Health Research, Clemson University, Clemson, SC, USA
| | - Linda Agyemang
- Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, USA
| | - Ellen S Stein
- Department of Medicine, University of California San Francisco, San Francisco, CA, USA
| | - Aurielle Thomas
- College of Pharmacy, University of Rhode Island, Providence, RI, USA
| | - Courtney Borsuk
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | - Kendra L Blalock
- Department of Medicine, University of Washington, Seattle, WA, USA
| | - Samuel Wilkinson
- Office of Research Program Management, West Virginia University School of Medicine, Morgantown, WV, USA
| | - Katherine Wagner
- University of New Mexico Health Sciences Center, Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA
| | - Jillian Roche
- Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | | | - Jessica Anderson
- University of New Mexico Health Sciences Center, Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA
| | - Vanessa Jacobsohn
- Department of Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, NM, USA
| | - Anne F Luetkemeyer
- Department of Medicine, University of California San Francisco, San Francisco, CA, USA
| | - Oluwaseun Falade-Nwulia
- Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Kimberly Page
- University of New Mexico Health Sciences Center, Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA
| | | |
Collapse
|
44
|
Luu B, Ruderman S, Nance R, Delaney JAC, Ma J, Hahn A, Heckbert SR, Budoff MJ, Crothers K, Mathews WC, Christopolous K, Hunt PW, Eron J, Moore R, Keruly J, Lober WB, Burkholder GA, Willig A, Chander G, McCaul ME, Cropsey K, O'Cleirigh C, Peter I, Feinstein M, Tsui JI, Lindstroem S, Saag M, Kitahata MM, Crane HM, Drumright LN, Whitney BM. Tobacco smoking and binge alcohol use are associated with incident venous thromboembolism in an HIV cohort. HIV Med 2022; 23:1051-1060. [PMID: 35343038 PMCID: PMC9515244 DOI: 10.1111/hiv.13309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2021] [Revised: 01/27/2022] [Accepted: 03/14/2022] [Indexed: 01/28/2023]
Abstract
BACKGROUND People with HIV (PWH) are at increased risk of cardiovascular comorbidities and substance use is a potential predisposing factor. We evaluated associations of tobacco smoking and alcohol use with venous thromboembolism (VTE) in PWH. METHODS We assessed incident, centrally adjudicated VTE among 12 957 PWH within the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort between January 2009 and December 2018. Using separate Cox proportional hazards models, we evaluated associations of time-updated alcohol and cigarette use with VTE, adjusting for demographic and clinical characteristics. Smoking was evaluated as pack-years and never, former, or current use with current cigarettes per day. Alcohol use was parameterized using categorical and continuous alcohol use score, frequency of use, and binge frequency. RESULTS During a median of 3.6 years of follow-up, 213 PWH developed a VTE. One-third of PWH reported binge drinking and 40% reported currently smoking. In adjusted analyses, risk of VTE was increased among both current (HR: 1.44, 95% CI: 1.02-2.03) and former (HR: 1.44, 95% CI: 0.99-2.07) smokers compared to PWH who never smoked. Additionally, total pack-years among ever-smokers (HR: 1.10 per 5 pack-years; 95% CI: 1.03-1.18) was associated with incident VTE in a dose-dependent manner. Frequency of binge drinking was associated with incident VTE (HR: 1.30 per 7 days/month, 95% CI: 1.11-1.52); however, alcohol use frequency was not. Severity of alcohol use was not significantly associated with VTE. CONCLUSIONS Current smoking and pack-year smoking history were dose-dependently associated with incident VTE among PWH in CNICS. Binge drinking was also associated with VTE. Interventions for smoking and binge drinking may decrease VTE risk among PWH.
Collapse
Affiliation(s)
- Brandon Luu
- Northern Ontario School of Medicine, Thunder Bay, Ontario, Canada
| | | | - Robin Nance
- University of Washington, Seattle, Washington, USA
| | - Joseph A C Delaney
- University of Washington, Seattle, Washington, USA
- University of Manitoba, Winnipeg, Manitoba, Canada
| | - Jimmy Ma
- University of Washington, Seattle, Washington, USA
| | - Andrew Hahn
- University of Washington, Seattle, Washington, USA
| | | | | | | | | | | | - Peter W Hunt
- University of California, San Francisco, California, USA
| | - Joseph Eron
- University of North Carolina, Chapel Hill, North Carolina, USA
| | | | | | | | | | - Amanda Willig
- University of Alabama at Birmingham, Birmingham, Alabama, USA
| | | | | | - Karen Cropsey
- University of Alabama at Birmingham, Birmingham, Alabama, USA
| | | | - Inga Peter
- Mount Sinai Hospital, New York, New York, USA
| | | | | | | | - Michael Saag
- University of Alabama at Birmingham, Birmingham, Alabama, USA
| | | | | | | | | |
Collapse
|
45
|
Barry MP, Austin EJ, Bhatraju EP, Glick SN, Stekler JD, Tung EL, Hansen RN, Williams EC, Gojic AJ, Pickering EI, Tsui JI. Qualitative inquiry into perceptions of HIV pre-exposure prophylaxis among people who inject drugs living with hepatitis C in Seattle, WA, USA. Harm Reduct J 2022; 19:121. [PMID: 36320005 PMCID: PMC9628120 DOI: 10.1186/s12954-022-00706-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Accepted: 10/07/2022] [Indexed: 01/24/2023] Open
Abstract
BACKGROUND The incidence of HIV among persons who inject drugs (PWID) in the USA has been increasing since 2014, signaling the need to identify effective ways to engage PWID in HIV prevention services, namely pre-exposure prophylaxis (PrEP). Yet, the uptake of PrEP in this population is minimal compared to other populations at risk of HIV acquisition. In this work, we sought to explore knowledge, attitudes, and perspectives of PrEP acceptability among PWID. METHODS In the context of a pilot study to explore the acceptability of pharmacy-based hepatitis C virus (HCV) treatment, we conducted semi-structured interviews (n = 24) and focus groups (n = 4, 16 participants) with people who were living with HCV and reported active injection drug use (≤ 90 days since last use). Participants were asked open-ended questions about their familiarity with and motivation to use PrEP. As part of a sub-analysis focused on PrEP, qualitative data were analyzed using a Rapid Assessment Process, where three coders used structured templates to summarize qualitative data and iteratively reviewed coded templates to identify themes. Participants also completed short quantitative questionnaires regarding drug use history and attitudes toward health concerns. RESULTS Forty-seven percent of participants expressed having little or no concern regarding HIV acquisition. Targeted analyses focused on HIV prevention identified three themes, which help characterize behavioral determinants of nonadoption. First, knowledge of PrEP was limited among PWID and influenced by infrequent open community discussions around HIV risk. Second, PWID perceived sexual behaviors-but not injection drug use-as a motivator for HIV risk prevention. Finally, PWID identified many individual and environmental barriers that hinder PrEP uptake. CONCLUSION Among PWID, PrEP is rarely discussed and concerns about the feasibility of using daily PrEP are common. Taken with the prevalent perception that drug use is not a high risk for HIV acquisition, our findings point to opportunities for public health work to target PrEP education to PWID and to leverage other successful interventions for PWID as an opportunity to provide PrEP to this vulnerable population.
Collapse
Affiliation(s)
- Michael P Barry
- Department of Epidemiology, Hans Rosling Center, School of Public Health, University of Washington, 3980 15th Ave. NE, 8th Floor, Box 351619, Seattle, WA, 98195, USA
- HIV/STD Program, Public Health - Seattle and King County, 401 5th Ave. Suite 1300, Seattle, WA, 98104, USA
| | - Elizabeth J Austin
- Department of Health Systems and Population Health, Hans Rosling Center, School of Public Health, University of Washington, 3980 15th Ave. NE, 4th Floor, Box 351621, Seattle, WA, 98195, USA
| | - Elenore P Bhatraju
- Division of General Internal Medicine, Department of Medicine, Harborview Medical Center, University of Washington, 325 9th Avenue, Box 359780, Seattle, WA, 98104, USA
| | - Sara N Glick
- HIV/STD Program, Public Health - Seattle and King County, 401 5th Ave. Suite 1300, Seattle, WA, 98104, USA
- Division of Allergy and Infectious Diseases, University of Washington, 1959 NE Pacific St., Box 356423, Seattle, WA, 98195, USA
| | - Joanne D Stekler
- Department of Epidemiology, Hans Rosling Center, School of Public Health, University of Washington, 3980 15th Ave. NE, 8th Floor, Box 351619, Seattle, WA, 98195, USA
- Division of Allergy and Infectious Diseases, University of Washington, 1959 NE Pacific St., Box 356423, Seattle, WA, 98195, USA
- Department of Global Health, Hans Rosling Center, School of Public Health, University of Washington, 3980 15th Ave. NE, 7th Floor, Seattle, WA, 98195, USA
| | - Elyse L Tung
- Kelley-Ross Pharmacy Group, Seattle, WA, USA
- Department of Pharmacy, University of Washington, H375 Health Science Building, Box 357630, Seattle, WA, 98195-7630, USA
| | - Ryan N Hansen
- Department of Health Systems and Population Health, Hans Rosling Center, School of Public Health, University of Washington, 3980 15th Ave. NE, 4th Floor, Box 351621, Seattle, WA, 98195, USA
- Kelley-Ross Pharmacy Group, Seattle, WA, USA
- Department of Pharmacy, University of Washington, H375 Health Science Building, Box 357630, Seattle, WA, 98195-7630, USA
| | - Emily C Williams
- Department of Health Systems and Population Health, Hans Rosling Center, School of Public Health, University of Washington, 3980 15th Ave. NE, 4th Floor, Box 351621, Seattle, WA, 98195, USA
- Center of Innovation for Veteran-Centered and Value-Driven Care, Health Services Research and Development, VA Puget Sound, 1660 South Columbia Way, Building 101, Room 4E51, Seattle, WA, 98108, USA
| | - Alexander J Gojic
- Division of General Internal Medicine, Department of Medicine, Harborview Medical Center, University of Washington, 325 9th Avenue, Box 359780, Seattle, WA, 98104, USA
| | - Eleanor I Pickering
- Division of General Internal Medicine, Department of Medicine, Harborview Medical Center, University of Washington, 325 9th Avenue, Box 359780, Seattle, WA, 98104, USA
- Department of Social and Behavioral Sciences, Yale School of Public Health, 60 College Street, Suite 316, New Haven, CT, 06510, USA
| | - Judith I Tsui
- Division of General Internal Medicine, Department of Medicine, Harborview Medical Center, University of Washington, 325 9th Avenue, Box 359780, Seattle, WA, 98104, USA.
| |
Collapse
|
46
|
Korthuis PT, Cook RR, Foot CA, Leichtling G, Tsui JI, Stopka TJ, Leahy J, Jenkins WD, Baker R, Chan B, Crane HM, Cooper HL, Feinberg J, Zule WA, Go VF, Estadt AT, Nance RM, Smith GS, Westergaard RP, Van Ham B, Brown R, Young AM. Association of Methamphetamine and Opioid Use With Nonfatal Overdose in Rural Communities. JAMA Netw Open 2022; 5:e2226544. [PMID: 35969400 PMCID: PMC9379740 DOI: 10.1001/jamanetworkopen.2022.26544] [Citation(s) in RCA: 23] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Accepted: 06/23/2022] [Indexed: 01/29/2023] Open
Abstract
Importance Overdoses continue to increase in the US, but the contribution of methamphetamine use is understudied in rural communities. Objective To estimate the prevalence of methamphetamine use and its correlates among people who use drugs (PWUD) in rural US communities and to determine whether methamphetamine use is associated with increased nonfatal overdoses. Design, Setting, and Participants From January 2018 through March 2020, the National Rural Opioid Initiative conducted cross-sectional surveys of PWUD in rural communities in 10 states (Illinois, Kentucky, New Hampshire, Massachusetts, North Carolina, Ohio, Oregon, Vermont, West Virginia, and Wisconsin). Participants included rural PWUD who reported any past-30-day injection drug use or noninjection opioid use to get high. A modified chain-referral sampling strategy identified seeds who referred others using drugs. Data analysis was performed from May 2021 to January 2022. Exposures Use of methamphetamine alone, opioids alone, or both. Main Outcomes and Measures Unweighted and weighted prevalence of methamphetamine use, any past-180-day nonfatal overdose, and number of lifetime nonfatal overdoses. Results Among the 3048 participants, 1737 (57%) were male, 2576 (85%) were White, and 225 (7.4%) were American Indian; the mean (SD) age was 36 (10) years. Most participants (1878 of 2970 participants with any opioid or methamphetamine use [63%]) reported co-use of methamphetamine and opioids, followed by opioids alone (702 participants [24%]), and methamphetamine alone (390 participants [13%]). The estimated unweighted prevalence of methamphetamine use was 80% (95% CI, 64%-90%), and the estimated weighted prevalence was 79% (95% CI, 57%-91%). Nonfatal overdose was greatest in people using both methamphetamine and opioids (395 of 2854 participants with nonmissing overdose data [22%]) vs opioids alone (99 participants [14%]) or methamphetamine alone (23 participants [6%]). Co-use of methamphetamine and opioids was associated with greater nonfatal overdose compared with opioid use alone (adjusted odds ratio, 1.45; 95% CI, 1.08-1.94; P = .01) and methamphetamine use alone (adjusted odds ratio, 3.26; 95% CI, 2.06-5.14; P < .001). Those with co-use had a mean (SD) of 2.4 (4.2) (median [IQR], 1 [0-3]) lifetime overdoses compared with 1.7 (3.5) (median [IQR], 0 [0-2]) among those using opioids alone (adjusted rate ratio, 1.20; 95% CI, 1.01-1.43; P = .04), and 1.1 (2.9) (median [IQR], 0 [0-1]) among those using methamphetamine alone (adjusted rate ratio, 1.81; 95% CI, 1.45-2.27; P < .001). Participants with co-use most often reported having tried and failed to access substance use treatment: 827 participants (44%) for both, 117 participants (30%) for methamphetamine alone, and 252 participants (36%) for opioids alone (χ22 = 33.8; P < .001). Only 66 participants (17%) using methamphetamine alone had naloxone. Conclusions and Relevance These findings suggest that harm reduction and substance use disorder treatment interventions must address both methamphetamine and opioids to decrease overdose in rural communities.
Collapse
Affiliation(s)
- P. Todd Korthuis
- Section of Addiction Medicine, Department of Medicine, Oregon Health & Science University, Portland
- Oregon Health & Science University–Portland State University School of Public Health, Portland
| | - Ryan R. Cook
- Section of Addiction Medicine, Department of Medicine, Oregon Health & Science University, Portland
| | - Canyon A. Foot
- Section of Addiction Medicine, Department of Medicine, Oregon Health & Science University, Portland
| | | | - Judith I. Tsui
- Section of General Internal Medicine, Department of Medicine, University of Washington, Seattle
| | - Thomas J. Stopka
- Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts
| | | | - Wiley D. Jenkins
- Department of Population Science and Policy, Southern Illinois University School of Medicine, Springfield
| | - Robin Baker
- Oregon Health & Science University–Portland State University School of Public Health, Portland
| | - Brian Chan
- Section of Addiction Medicine, Department of Medicine, Oregon Health & Science University, Portland
| | - Heidi M. Crane
- Section of General Internal Medicine, Department of Medicine, University of Washington, Seattle
| | - Hannah L. Cooper
- Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, Georgia
| | - Judith Feinberg
- Department of Behavioral Medicine and Psychiatry, West Virginia University School of Medicine, Morgantown
- Department of Medicine, Infectious Diseases, West Virginia University School of Medicine, Morgantown
| | | | - Vivian F. Go
- Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina–Chapel Hill, Chapel Hill
| | - Angela T. Estadt
- Division of Epidemiology, College of Public Health, The Ohio State University, Columbus
| | - Robin M. Nance
- Section of General Internal Medicine, Department of Medicine, University of Washington, Seattle
| | - Gordon S. Smith
- Department of Epidemiology and Biostatistics, School of Public Health, West Virginia University, Morgantown
| | - Ryan P. Westergaard
- Division of Infectious Diseases, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison
| | - Brent Van Ham
- Department of Population Science and Policy, Southern Illinois University School of Medicine, Springfield
| | - Randall Brown
- Department of Family Medicine & Community Health, University of Wisconsin School of Medicine & Public Health, Madison
| | - April M. Young
- Department of Epidemiology, University of Kentucky, Lexington
- Center on Drug and Alcohol Research, University of Kentucky, Lexington
| |
Collapse
|
47
|
Frost MC, Richards JE, Blosnich JR, Hawkins EJ, Tsui JI, Edelman EJ, Williams EC. Association between clinically recognized suicidality and subsequent initiation or continuation of medications for opioid use disorder. Drug Alcohol Depend 2022; 237:109521. [PMID: 35716644 PMCID: PMC9546132 DOI: 10.1016/j.drugalcdep.2022.109521] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 05/09/2022] [Accepted: 05/28/2022] [Indexed: 11/21/2022]
Abstract
BACKGROUND Among individuals with opioid use disorder (OUD), medications for OUD (MOUD) may lower suicide risk. Therefore, it is important that individuals with OUD and suicidality receive MOUD. This study examined associations between clinically recognized suicidality and subsequent initiation or continuation of MOUD among patients with OUD in the national Veterans Health Administration (VA). METHODS Electronic health record data were extracted for outpatients with OUD who received VA care 10/1/2016-7/31/2017. Suicidality was measured using diagnostic codes for suicidal ideation/attempt and patient record flags. Analyses were conducted separately among patients without prior-year MOUD receipt to examine MOUD initiation, and with prior-year MOUD receipt to examine MOUD continuation. Poisson regression models estimated likelihood of MOUD receipt in the following year for patients with prior-year suicidality relative to those without. Models were adjusted for sociodemographic and clinical characteristics. RESULTS Among 20,085 patients with no prior-year MOUD, 12% had suicidality and 12% received MOUD in the following year. Suicidality was positively associated with MOUD initiation (adjusted incidence rate ratio [aIRR]: 1.15, 95% confidence interval [CI]: 1.04-1.28). Among 10,162 patients with prior-year MOUD, 9% had suicidality and 84% received MOUD in the following year. Suicidality was negatively associated with MOUD continuation (aIRR: 0.95, 95% CI 0.91-0.98). CONCLUSIONS Among VA patients with OUD, clinically recognized suicidality may increase likelihood of MOUD initiation but decrease likelihood of continuation. Efforts to increase initiation overall and to support retention for patients with suicidality are needed.
Collapse
Affiliation(s)
- Madeline C Frost
- Health Services Research & Development (HSR&D) Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs (VA) Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA 98108, USA; Department of Health Systems and Population Health, University of Washington School of Public Health, 1959 NE Pacific St, Seattle, WA 98195, USA.
| | - Julie E Richards
- Department of Health Systems and Population Health, University of Washington School of Public Health, 1959 NE Pacific St, Seattle, WA 98195, USA; Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101, USA.
| | - John R Blosnich
- Suzanne Dworak-Peck School of Social Work, University of Southern California, 669W 34th St, Los Angeles, CA 90089, USA; Health Services Research & Development (HSR&D) Center for Health Equity Research and Promotion, Veterans Affairs (VA) Pittsburgh Healthcare System, University Drive (151C), Pittsburgh, PA 15240, USA.
| | - Eric J Hawkins
- Health Services Research & Development (HSR&D) Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs (VA) Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA 98108, USA; Center of Excellence in Substance Addiction Treatment and Education, Veterans Affairs (VA) Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA 98108, USA; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, 1959 NE Pacific St, Seattle, WA 98195, USA.
| | - Judith I Tsui
- Department of Medicine, University of Washington School of Medicine, 1959 NE Pacific St, Seattle, WA 98195, USA.
| | - E Jennifer Edelman
- Department of Internal Medicine, Yale School of Medicine, 333 Cedar St, New Haven, CT 06510, USA.
| | - Emily C Williams
- Health Services Research & Development (HSR&D) Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs (VA) Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA 98108, USA; Department of Health Systems and Population Health, University of Washington School of Public Health, 1959 NE Pacific St, Seattle, WA 98195, USA.
| |
Collapse
|
48
|
Jenkins RA, Whitney BM, Nance RM, Allen TM, Cooper HLF, Feinberg J, Fredericksen R, Friedmann PD, Go VF, Jenkins WD, Korthuis PT, Miller WC, Pho MT, Rudolph AE, Seal DW, Smith GS, Stopka TJ, Westergaard RP, Young AM, Zule WA, Delaney JAC, Tsui JI, Crane HM. The Rural Opioid Initiative Consortium description: providing evidence to Understand the Fourth Wave of the Opioid Crisis. Addict Sci Clin Pract 2022; 17:38. [PMID: 35883197 PMCID: PMC9321271 DOI: 10.1186/s13722-022-00322-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2022] [Accepted: 07/11/2022] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVE To characterize and address the opioid crisis disproportionately impacting rural U.S. regions. METHODS The Rural Opioid Initiative (ROI) is a two-phase project to collect and harmonize quantitative and qualitative data and develop tailored interventions to address rural opioid use. The baseline quantitative survey data from people who use drugs (PWUD) characterizes the current opioid epidemic (2018-2020) in eight geographically diverse regions. RESULTS Among 3,084 PWUD, 92% reported ever injecting drugs, 86% reported using opioids (most often heroin) and 74% reported using methamphetamine to get high in the past 30 days; 53% experienced homelessness in the prior 6 months; and 49% had ever overdosed. Syringe service program use varied by region and 53% had ever received an overdose kit or naloxone prescription. Less than half (48%) ever received medication for opioid use disorder (MOUD). CONCLUSIONS The ROI combines data across eight rural regions to better understand drug use including drivers and potential interventions in rural areas with limited resources. Baseline ROI data demonstrate extensive overlap between opioid and methamphetamine use, high homelessness rates, inadequate access to MOUD, and other unmet needs among PWUD in the rural U.S. By combining data across studies, the ROI provides much greater statistical power to address research questions and better understand the syndemic of infectious diseases and drug use in rural settings including unmet treatment needs.
Collapse
Affiliation(s)
- Richard A. Jenkins
- Prevention Research Branch, National Institute on Drug Abuse, 3WFN MSC 6024, 301 North Stonestreet Ave, Bethesda, MD 20892 USA
| | - Bridget M. Whitney
- University of Washington Harborview Medical Center, 325 9th Ave, Box 359931, Seattle, WA 98106 USA
| | - Robin M. Nance
- University of Washington Harborview Medical Center, 325 9th Ave, Box 359931, Seattle, WA 98106 USA
| | - Todd M. Allen
- Ragon Institute of MGH, MIT and Harvard, Rm 764 400 Technology Square, Cambridge, MA 02139 USA
| | - Hannah L. F. Cooper
- Rollins School of Public Health, Emory University, Grace Crum Rollins Building 1518 Clifton Road, Atlanta, GA 30322 USA
| | - Judith Feinberg
- West Virginia University, 930 Chestnut Ridge Road, PO Box 9156, Morgantown, WV 26505 USA
| | - Rob Fredericksen
- University of Washington Harborview Medical Center, 325 9th Ave, Box 359931, Seattle, WA 98106 USA
| | - Peter D. Friedmann
- Baystate Medical Center—University of Massachusetts, Office of Research, UMass Chan Medical School - Baystate, 3601 Main Street, 3rd Floor, Springfield, MA 01199 USA
| | - Vivian F. Go
- University of North Carolina—Chapel Hill, 363 Rosenau Hall CB# 7440, Chapel Hill, NC 27599 USA
| | - Wiley D. Jenkins
- Southern Illinois University, 201 E Madison Street, Springfield, IL 62702 USA
| | - P. Todd Korthuis
- Oregon Health & Science University, 3270 Southwest Pavilion Loop OHSU Physicians Pavilion, Suite 350, Portland, OR 97239 USA
| | - William C. Miller
- The Ohio State University, 302 Cunz Hall 1841 Neil Ave, Columbus, OH 43210 USA
| | - Mai T. Pho
- University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637 USA
| | - Abby E. Rudolph
- Department of Epidemiology and Biostatistics, Temple University College of Public Health, 1301 Cecil B Moore Avenue, Ritter Annex 905, Philadelphia, PA USA
| | - David W. Seal
- Tulane University, 1440 Canal Street, Suite 2210, New Orleans, LA 70112 USA
| | - Gordon S. Smith
- West Virginia University, 930 Chestnut Ridge Road, PO Box 9156, Morgantown, WV 26505 USA
- College of Pharmacy, University of Manitoba, Apotex Centre, 750 McDermot Ave. W, Winnipeg, MB R3E 0T5 Canada
| | - Thomas J. Stopka
- Tufts University School of Medicine Public Health and Community Medicine, 136 Harrison Avenue, Boston, MA 02111 USA
| | - Ryan P. Westergaard
- University of Wisconsin-Madison, 1685 Highland Avenue, 5th Floor, Madison, WI 53705-2281 USA
| | - April M. Young
- University of Kentucky, 760 Press Avenue Suite 280, Lexington, KY 40536 USA
| | - William A. Zule
- RTI International, 3040 E. Cornwallis Road, PO Box 12194, Research Triangle Park, NC 2709-2194 USA
| | - Joseph A. C. Delaney
- College of Pharmacy, University of Manitoba, Apotex Centre, 750 McDermot Ave. W, Winnipeg, MB R3E 0T5 Canada
| | - Judith I. Tsui
- University of Washington Harborview Medical Center, 325 9th Ave, Box 359931, Seattle, WA 98106 USA
| | - Heidi M. Crane
- University of Washington Harborview Medical Center, 325 9th Ave, Box 359931, Seattle, WA 98106 USA
| | - the Rural Opioid Initiative
- Prevention Research Branch, National Institute on Drug Abuse, 3WFN MSC 6024, 301 North Stonestreet Ave, Bethesda, MD 20892 USA
- University of Washington Harborview Medical Center, 325 9th Ave, Box 359931, Seattle, WA 98106 USA
- Ragon Institute of MGH, MIT and Harvard, Rm 764 400 Technology Square, Cambridge, MA 02139 USA
- Rollins School of Public Health, Emory University, Grace Crum Rollins Building 1518 Clifton Road, Atlanta, GA 30322 USA
- West Virginia University, 930 Chestnut Ridge Road, PO Box 9156, Morgantown, WV 26505 USA
- Baystate Medical Center—University of Massachusetts, Office of Research, UMass Chan Medical School - Baystate, 3601 Main Street, 3rd Floor, Springfield, MA 01199 USA
- University of North Carolina—Chapel Hill, 363 Rosenau Hall CB# 7440, Chapel Hill, NC 27599 USA
- Southern Illinois University, 201 E Madison Street, Springfield, IL 62702 USA
- Oregon Health & Science University, 3270 Southwest Pavilion Loop OHSU Physicians Pavilion, Suite 350, Portland, OR 97239 USA
- The Ohio State University, 302 Cunz Hall 1841 Neil Ave, Columbus, OH 43210 USA
- University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637 USA
- Department of Epidemiology and Biostatistics, Temple University College of Public Health, 1301 Cecil B Moore Avenue, Ritter Annex 905, Philadelphia, PA USA
- Tulane University, 1440 Canal Street, Suite 2210, New Orleans, LA 70112 USA
- Tufts University School of Medicine Public Health and Community Medicine, 136 Harrison Avenue, Boston, MA 02111 USA
- University of Wisconsin-Madison, 1685 Highland Avenue, 5th Floor, Madison, WI 53705-2281 USA
- University of Kentucky, 760 Press Avenue Suite 280, Lexington, KY 40536 USA
- RTI International, 3040 E. Cornwallis Road, PO Box 12194, Research Triangle Park, NC 2709-2194 USA
- College of Pharmacy, University of Manitoba, Apotex Centre, 750 McDermot Ave. W, Winnipeg, MB R3E 0T5 Canada
| |
Collapse
|
49
|
Tsui JI, Campbell ANC, Pavlicova M, Choo TH, Lee JD, Cook RR, Shulman M, Nunes EV, Rotrosen J. Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone. Drug Alcohol Depend 2022; 236:109469. [PMID: 35605529 PMCID: PMC10796081 DOI: 10.1016/j.drugalcdep.2022.109469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Revised: 03/22/2022] [Accepted: 04/17/2022] [Indexed: 11/03/2022]
Abstract
BACKGROUND Methamphetamine use is increasing among persons with opioid use disorder (OUD). The study aims were to describe methamphetamine/amphetamine (MA/A) use among patients treated for OUD with buprenorphine/naloxone (BUP-NX) or extended-release naltrexone (XR-NTX), and to explore associations between treatment arm and MA/A use. METHODS Secondary analysis of data from a multi-site, open-label, randomized controlled trial of XR-NTX versus BUP-NX for 24 weeks. The outcome variable was MA/A use defined by either positive urine drug toxicology or self-report. The main predictor was treatment assignment (BUP-NX v. XR-NTX). Longitudinal mixed-effects logistic regression models were fit to model the odds of MA/A use during the study. Additional predictors included study visit and baseline MA/A use. RESULTS Among the sample of 570 participants with OUD, baseline use of MA/A was observed in 105 (18.4%). There was no significant treatment effect over the study period, though BUP-NX subjects, on average, had about half the odds of MA/A use compared to XR-NTX subjects (OR=0.50; p = 0.051). In the same model, baseline MA/A use and study visit were both significantly associated with MA/A use over time. CONCLUSION In this sample of treated OUD patients, nearly a fifth of participants had MA/A use at baseline and the frequency of use did not decline over time: in fact, the odds of use slightly increased for each later visit. These secondary analyses found no significant difference in MA/A use between BUP-NX and XR-NTX treatment arms, however, the observation of less MA/A in the buprenorphine arm merits further investigation. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov (NCT02032433).
Collapse
Affiliation(s)
- Judith I Tsui
- Department of Medicine, University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA 98195-6420, USA.
| | - Aimee N C Campbell
- Department of Psychiatry, Columbia University Irving Medical Center and New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA
| | - Martina Pavlicova
- Department of Biostatistics, Columbia University, 722 West 168th St., New York, NY 10032, USA
| | - Tse-Hwei Choo
- Department of Psychiatry, Columbia University Irving Medical Center and New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA
| | - Joshua D Lee
- Department of Medicine, New York University, 550 First Avenue, New York, NY 10016, USA
| | - Ryan R Cook
- Department of Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
| | - Matisyahu Shulman
- Department of Psychiatry, Columbia University Irving Medical Center and New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA
| | - Edward V Nunes
- Department of Psychiatry, Columbia University Irving Medical Center and New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA
| | - John Rotrosen
- Psychiatry, New York University, 550 First Avenue, New York, NY 10016, USA
| |
Collapse
|
50
|
Austin EJ, Tsui JI, Barry MP, Tung E, Glick SN, Ninburg M, Williams EC. Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma. J Subst Abuse Treat 2022; 137:108684. [PMID: 34911656 PMCID: PMC10586539 DOI: 10.1016/j.jsat.2021.108684] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2021] [Revised: 08/13/2021] [Accepted: 11/29/2021] [Indexed: 11/25/2022]
Abstract
INTRODUCTION People who inject drugs (PWID) have complex health needs and often experience poor health outcomes. For PWID, intersectional experiences of stigma and other social vulnerabilities may influence their experiences navigating medical care. We conducted a targeted subanalysis of qualitative interview data collected to inform development of a community-pharmacist care model for hepatitis C (HCV) among PWID to explore intersectional influences on health care-seeking experiences. METHODS The study recruited participants from community organizations in Seattle, Washington, and participants were eligible if they reported injection drug use within 3 months and having HCV. Study staff conducted semi-structured interviews and two independent coders transcribed and initially analyzed them using a Rapid Assessment Process, guided by the Consolidated Framework for Implementation Research. Themes emerged regarding intersections of stigma and social vulnerabilities; thus, we conducted a targeted subanalysis guided by Fundamental Cause Theory and Earnshaw et al.'s Stigma Framework. RESULTS Forty participants (65% male; 47% non-white) reported multiple social vulnerabilities (e.g., regarding unstable housing and food insecurity). Qualitative analysis identified that receiving health care in the context of social vulnerability is challenging and burdensome (Theme 1); health care interactions are fraught with stigma stemming from intersectional vulnerabilities (Theme 2); and the belief that abstaining from drug use is needed to prove worthiness for care (Theme 3). PWID described experiencing multiple social vulnerabilities (e.g., unmet basic needs) that made seeking health care burdensome. Interactions with health care teams further reinforced participants' feelings of shame about their drug use, which influenced how participants expressed their care preferences and felt heard by providers. And as PWID navigated health care, they felt that their status as an active drug user was used to control and sometimes coerce their access to services, discouraging PWID from seeking needed care. CONCLUSIONS Stigma and social vulnerabilities play a pervasive and intersecting role in the health care-seeking experiences of PWID and negatively impact their ability to navigate and receive care they need. Evidence-based stigma reduction interventions at multiple levels, coupled with person-centered approaches to care delivery, may help to mitigate negative impacts.
Collapse
Affiliation(s)
- Elizabeth J Austin
- Department of Health Systems and Population Health, University of Washington, Seattle, WA, United States of America
| | - Judith I Tsui
- Department of Medicine, Division of General Internal Medicine, University of Washington, Seattle, WA, United States of America.
| | - Michael P Barry
- Department of Epidemiology, University of Washington, Seattle, WA, United States of America; HIV/STD Program, Public Health - Seattle & King County, Seattle, WA, United States of America
| | - Elyse Tung
- Department of Pharmacy, University of Washington, Seattle, WA, United States of America; Kelley-Ross Pharmacy Group, Seattle, WA, United States of America
| | - Sara N Glick
- HIV/STD Program, Public Health - Seattle & King County, Seattle, WA, United States of America; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, United States of America
| | - Michael Ninburg
- Hepatitis Education Project, Seattle, WA, United States of America
| | - Emily C Williams
- Department of Health Systems and Population Health, University of Washington, Seattle, WA, United States of America; Center of Innovation for Veteran-Centered and Value-Driven Care, Health Services Research & Development, VA Puget Sound, Seattle, WA, United States of America
| |
Collapse
|